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ABSTRACT 
The purpose of this study was to design, evaluate, and determine 
the cost benefit of a pharmacokinetic service for home-based patients. 
Four randomly selected patient populations were used in evaluating the 
service for six months. The experimental group consisted of 17 patients 
who were under the care of family practice physicians in private 
practice and who received pharmacokinetic consultation and monitoring by 
a pharmacist as a home health care service. The retrospective control 
consisted of the same 17 patients of the experimental group whose past 
medical history for a period of six months was used. The concurrent 
control consisted of 17 patients who were concurrently treated by the 
same family practice physicians in private practice who treated the 
patients in the experimental group. The fourth group consisted of 17 
patients ~Tho were concurrently treated by family practice physicians in 
a general hospital outpatient clinic. · 
The service was evaluated by comparing the following variables: 
serum levels ordered, serum levels ordered inappropriately, physicians' 
office visits, hospitalizations secondary to pulmonary problems, and 
emergency room visits secondary to pulmonary problems. A one-way 
analysis of variance, Scheffe's post hoc test, and t test were used to 
analyze the results. There was a significant difference (P < 0.05) in 
the number of inappropriate levels ordered, physician's office visits, 
and emergency room visits. The cost of the service was $134 and the 
benefit was $218. It was concluded that a homebased pharmacokinetic 
service is cost beneficial in this patient population. 
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II!TRO!:>UCTIOI: 
Historical Sketch 
ThrouGhout the aGes, manki nd ' s need for remedies for his ailments 
has been one of his primar y concerns . This need has been tended to at 
various stazes of civilization by maBicians , r eligious pries ts , 
priest-physicians , physician-drUGGists, and quacks . In l a t er year s , 
such needs were provided for by a distinct professional group which 
specialized in the art of dispensing remedies tocether with counsel on 
their use. From t he time when the art of dispensing became recognized 
as a separate profession , a until the dawn of the scientific era, the ar t 
of dispensing and the pr ofession of pharmacy progressed very little . It 
was the influence of the sci entific method that prompted many 
professi ons to the hei gh t of t he i r pr esent day accomplishments . 
AlthouGh the pr ofession of pharoacy traces its foundations to the 
anci ent days of Babyl on (1), it is onl y in r ecent years that pharmacy 
has become a scientific discipline . It is noteworthy that the 
humanitarian, sympathetic, person- to-person link with patients was the 
center of professional practic~ in those early days . This aspect of the 
profession was eclipsed by impersona l scientific practi ce for a while, 
but has made a comeback in t he past few years . 
a During the height of the Abbasside rule in Baghdad , circa 
800- 900 A.D . , the pharmacist or "Saidalani" was recognized as a dis tinct 
professional whose education and practice Has r egulated by the 
government ( 1). 
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The scientific method has had a gradual influence on the profession 
of pharmacy. By the early 1900s, the image of the pharmacist had 
changed from that of a master craftsman and herbalist to that of a 
professional basing his practice on the physical sciences. Apprentice-
ships had given way to college education, and rational compounding and 
dispensing had become norms of activities. Formal preparation in 
medical subjects did not parallel this scientific surge, which resulted 
in the pharmacist losing the role developed over the centuries, vthich 
involved health advice, patient consultation, and acquiring a new role 
which centered upon dispensing medications. 
The technological revolution in the chemical and pharmaceutical 
industry in the early and middle part of the 20th century did little to 
change this role. The pharmacist became more product oriented and more 
prepared academically to deal with the physics and chemistry of the drug 
entity. The availability of high-quality and economically manufactured 
products eroded his compounding role with an estimated 1% of all 
prescriptions being compounded as compared to about 80% in the 1920s 
(2). It also reduced his dispensing role to little more than counting 
pills and repackaging products with little or no use of his scientific 
expertise. He was ill-prepared to deal with the patients to whom he was 
dispensing or with the professionals with whom he was working. 
By the mid-1950s, it became apparent that the pharmacist's 
scientific background and physical science education had transformed him 
into an overqualified professional or tradesman in the eyes of some 
critics. It was also apparent that the profession of pharmacy would be 
at an impasse at some point in the near future if its practice options 
remained static. 
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The time h&d come for pharc&cy to face some important decisions. 
Perhaps a return to some of the practice activities it had inherited 
fro~ the ~ays of the apothecary was needed (3-6). Prodded by 
prosressively-cinded professional leaders and educators (5), and solidly 
entrenched in the sciences , pharmacy embarked on a transformation 
process with zeal and enthusiasc . A new landmark had been reached , and 
a new era was entered . 
The Inception of Clinical Phar;:tacv . I:any of the evolutionary 
changes in pharmacy have been fueled from within the profession . The 
quest for professionalism, the frustration that came Hith inapplicable 
competencies, and the vision and innovative spirit of individual 
pharmacists Here some of the internal forces. Outside the profession 
the influences included societal needs and demands, professional 
interactions within the health team, governmental regul ations and 
legislation, particularly those pertaining to the safety and efficacy of 
drug therapy . 
These and other forces l ed to what one might call the birth of t he 
concept of clinical phar~acy in the mid-1960s . This concept added new 
dimensions through which innovative modes of practice could be 
explored. It resulted in a shift of emphasis from the physical dru~ 
entity to the patient. It also started a neH dynamic era, with changes 
in concepts and functions taking place at a rapid pace . 
In the two decades since its inception , the concept of clinical 
pharmacy has gone through a number of transition states. The 1960s 
concept emphasized drug- use control in an institutional setting, a 
function attempting to ensure optimal safety in drug distribution and 
use . A decade l ater, the emphasis shifted to "drugs as they are 
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utilized by and in the patient; the joininG of the druG and the patient 
in an appropriate ~anner" (6). Still more recently, the emphasis has 
been shiftinG towards "providinc druG therapy on a disease- specific and 
patient-specific basis" ( 7) in a practice Jaodali ty resembling those of 
medical specialties (8). 
Despite al most two decades of actual recocnition as a ~uidinG 
concept in contec porary phar~acy practice , clinical pharoacy in most 
situations is still a voluntary and selective activity not ~andated by 
law, rule or regulation (9,10). Various innovative pharmaceutical 
activities and services have been evaluated, particularly in acute care 
settings. 
Contemporary Pharmacv Practice 
By the 1950s phar~acy's path of evolution had resulted in a 
dichotomous role based primarily on site or practice: a coomunity 
pharmacist and a hospital pharmacist (7). There was some distinction in 
practice and activities ; however , an exchange of roles was not difficult . 
Various roles e·xist today, but the present day division is not 
necessarily based upon site, but rather on the nature and mode of 
practice (11-13). Today, one finds one type of practice that is 
basically nondistributive and involves drug-related decision- making 
functions ; and another type that is basically concerned with the 
dispensing and distribution of druBs along traditional lines. 
The third type and perhaps the model for the future due to its 
current popularity is drug related decision-making functions with the 
dispensing of medication. One may find distributive and nondistributive 
practices in either a community or hospital setting, or one might find a 
mixture , sometimes unbalanced, of both types of practice in the s~e 
set tine . 
To characterize contemporary pharmacy practice as simply 
distributive and nondistributive is to do injustice to t he myriad of 
activities and functions that arc practiced by some phar macists today, 
Differentiations of roles and activities in the nondistr ibutive 
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functions have evolved, and are evolving continually. They ranse from 
simple counseling to sophisticated pharmacokinetic surveillance and 
monitoring of druG therapy, A pluralistic system of heal th care 
delivery has differentiated these functions into priLJary , secondary and 
tertiary levels of care (7). Such differentiations are geared to the 
demands and adaptability of the site of practice, pri marily institutional 
sites . However , with the present pace of change, it may not take long 
for many of these innovative differentiated practices to be i mplemented 
at community- based sites, 
Hospital pharmacists have been the most innovative of today 1 s 
practitioners . Perhaps it is the intrinsic nature of institutional care 
tha t has dictated or allowed for such leadership. The organizational 
setting, the acute and demanding nature of care, the interprofessional 
and intraprofessional challenses , and the infrastructure are a ll factors 
tha t have l ed to these innovations. Ind eed , the guidelines of the 
American Society of Hospital Pharmacists on clinical functions in 
institutional practice define in a concise manner the state of the art 
in clinical practice (8). Thus, it may be worthwhile to take a closer 
look at what has been accomplished in the past two decades , with the 
hope of identifying future implications. 
Clinical Pharmacy 
Clinical pharmacy activities depend to some extent on the site of 
practice . It ~iGht, therefore, be more relevant if one exaL1ined these 
activities accordinG to site, 
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Acute Care Activities. As auspicious as the advent of clinica l 
activities was for the profession, it uas by no weans fortuitous, One 
of the major moving forces that led to chane e was the safety of drug 
therapy, The hazards and proble~s of ~odern drug therapy were having an 
impact on the medical profession (14). The thalido~ide traGedies and 
the 1962 amendments to the 1938 Food, DruG and Cosmet ic Act further 
hiGhlighted the issue, especially by the media . 
Soon thereafter, voluminous professional literature on drug- r elated 
problems began to appear documenting specific instances and chartinG 
general principles . Adverse drug reactions were recognized as an 
important aspect of modern drug therapy, and their effects on prognosis, 
hospital stay and overall welfare were studied (15,16) , Drug- drug 
interactions and drug-food interactions became important concerns in 
drug therapy (17-20) . The influence of druGs on laboratory tests and 
diagnostic procedures was also recognized (17, 21 , 22 ,) . Medication 
errors resulting in inadequate therapy and unnecessary hospitalization, 
received more attention, r.lany similar drug-related issues became part 
of contemporary health care, 
The message Has clear. Increased vigil over drug therapy mus t be 
exercised by the medical profession and physicians were not adequately 
prepared for the task. Furthermore, they were already hard pressed to 
keep up vri th the changes in medical information. The opportunity was 
there for pharmacists to accept the challenge, and pioneering 
pharmacists started taking the first steps in clinical activities . 
Pharmacists began using their expertise in taking and keeping records of 
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pat i ents' ~edication hi stori es (23 ). They also started participatin~ in 
pat i ent care r ounds around hospital wards , monitoring druG therapy and 
observinG patients for adverse druG reactions ( 24 ). DruG interac tions 
wer e r eported by pharmacists as well as other health professionals, with 
all verified reports ~oing into a central a l ert systeo (25 ). Drug 
inforuation requests f rom other health pr ofessionals were handled with 
sl~ill and accur acy (25) . Patient education on druG therapy, coopl i ance , 
adverse drug effects, and drug react ions becane part of the 
institutional pharmacist's activity. On the whole, pharmaci s t s 
demons trated that s uch clinical activities benefited the patient ' s 
welfare and improve d the quality of health care (26-28). 
In the years that followed, the emphasis changed from safety alone 
to safety and efficacy of drug therapy. Pharmacists also started 
providing , upon request , written advice on the selection of drugs , 
appropriate dosage regi mens , l abor a tory data , nutritional support , and 
ther apeutic end points . Further, some institutions expec t ed clinical 
pharmac i sts to participate rou t inely in the management of medical 
emer gencies and adverse drug r eactions (8 , 29 , 30 ). 
The ASHP guide l i nes : Mi ni mum Standards for Pharmacies in 
Institutions (31) detercined the scope and qual ity of pharmaceutical 
ser vices provided . Standards were set for administration, facilities, 
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J drug distribution and control, drug information , and assuring rational 
i drug therapy a nd research. These standards were implemented to hel p 
regulate and assure the quality of existing services and duties of the 
pharmacist in today 1 s institutions. 
The 1985 Accreditation Manual for Hospitals s pecifies s t a ndards of 
pharmaceutical services to be maintained in accordance with accepted 
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ethical and professional practices (32) . These included the traditional 
du t ies such as provision, preparation, dispensing and stora8e of 
pharmaceuticals; updating the formulary; furnishing up-to-date pha rtaacy 
references. Other duties that are more clinically oriented are expected 
of the pharmacist according to the nanual, such as cooperating in the 
teaching and research proGrams of the hospital; maintaining a druG 
pr ofile for each patient, and revieHinG the patient drug reGi men for any 
potential interactions, interference or incompatibilities prior to 
dispensing drugs to the patient . 
The use of pharmacokinetic principles and calculations for the 
overall welfare and health care of the patient is now accepted as a 
specific clinical activity of the pharmacist in many institutions. In 
these instances, pharmacists use their expertise in pharmacol<inetics 
together with the patient's clinical data base and laboratory test 
results to participate in the design and adjustment of individuali zed 
dosage regimens ( 33,34) . Pharmacists also tal~e part in t he evaluation 
of unusual patient respons e to drug ther apy and recotu~end procedures fo r 
s erum drug assays and the appropriate timing for such assays . In a 
national survey carried out in 1979-1980 by Rich and coworkers, of 
74 r esponding hospitals, 27 hospitals ranging in s i ze f rom 44 to 1000 
beds responded that they were providing formal pharmacokinetic services 
either routinely or upon request (35). Updating the survey in December 
1983, the same authors reported an increase in that number from 27 to 63 
within 2 years (36) . Small as this number may be compared to the total 
number of acute care institutions in the country , it is significant in 
that pharmacokinetic consultations are on the increase . The 1985 Lilly 
Hospital Pharmacy Survey reported that the number of hospital pharmacies 
that provide a pharcacokinetic service has increased fourfold since 1978. 
The provision of clinical services or clinical activities i s not 
universal in u.s. hospitals (37). Before such functions become 
universal, it will require rJore perseverance on the part of clinically 
minded pharmacists and a ; reat deal more research into cost/effec t iveness 
issues (38,39). It is not sufficient for such services to have medical , 
social or psychological merits alone to become standards of pr ac tice. 
In an era of escal a tinG health care costs, pharmacists r;:ust justify t he 
cost of each innovation they introduce in addition to justifyinG them on 
medical grounds. 
Ambulatory-care Activities 
Institutionally based ambulatory-care activities. \lith the success 
of clinical pharmacy activities in acute care settings came the 
r ealization of the impor tance of clinical pharmacy in the overall care 
and w~ll-being of patients in other settings . It was a natura l 
opportunity for clinical pharmacists to transfer some of these 
innovative activities into hospital outpatient departments and clinics 
(40,25). Hany progr ams have been introduced extendi ng clinical pharmacy 
services to other areas such as the evaluation and monitorinG of 
hypertensive patients (41, 42); car e and monitoring of ambulatory 
psychiatric patients (43-45); anticoagulant ther apy (46) ; management of 
streptococcal throat infections (47); a role in the treatment of 
hemodialysis patients (4 8); the management of hypertensive patients 
(49); participation in aller gy clinics (50); a clinical role in 
psychiatric care (51); clinical pharmacy in methadone programs (52); and 
patient- oriented phar maceutical services for ambulatory diabetic 
patients (53). 
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The Indian Ilealth Service (IHS) has pioneered the area of primary 
health care (54,55). Phar~acists in IHS clinics have develope~, under 
physician-accepted standards of care, management protocols for 31 acute 
illnesses and seven chronic diseases (56 ,57). Under these protocols, 
pharmacists have provided primary health care including physical 
exar.1ination, diar;nosis and treatment. 
The Ap~alachian Regional Hospitals have also provided sioilar 
primary health care services in rural areas by teams of physic ians, 
nurses and pharmacists (58). The pharmacists in these settings provided 
patient education and primary health care in addition to their 
traditional dispensing services. 
The above few examples shov1 the diversity of scope in clinical 
pharmaceutical services and programs. Pharmacy pro£rams del iver 
comprehensive services to the patient at home, while others are 
predominantly institutional services. While some might be classified as 
home health care services, others are mere extensions of institutional 
services. 
Home Health Care Services. Home Health Care Services (HHCS) are 
comprehensive pharmaceutical services provided by clinical pharmacists 
to patients at home. These services involve patient education, 
counseling, and monitoring of therapy as well as distributive services. 
Patients are taught the essentials of self-medication by a clinical 
pharmacist or by a team of health professionals. Patients are also 
provided with all medication and ancillary products. The clinical 
pharmacist monitors the patient's therapy and consults with other health 
professionals on a regular basis. 
There were many f actors inducing the development of HHCS . The 
earliest incentives were economica l with patients beinG frequently 
hospitalized for prolonged periods merely to be provided \lith 
intravenous (IV) solutions or medications. The cost of prolonged or 
repeated hospi talizations could be greatly reduced if these patients 
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were properly trained and provided with the necessary equipment and 
supplies for self-medication (59). For example, O' Donnel esticated a 
50-80% savinG in home IV therapy over similar hospital-based services 
(60). Since then many other programs have been introduced and e valuated. 
Nold and Pathak studied the feasibility and cost/effectiveness of 
hospital-based clinical home services provided by the pharmacy 
department. These services included: a hemophilia proGram; cytarabine 
and 5-fluorouracil self-medication for cancer patients; dexamethasone 
for adrenalectomized patients; home heparin administration; total 
parenteral nutrition; calcitonin-salmon for patients with Paget's 
disease; narcotic analGetics for terminal cancer patients; and home IV 
antibiotic administration. Recently they started a hospital-based home 
pharmacokinetic monitoring service, a compl iance clinic and a pain 
clinic for its patients (61,62). 
These innovations have been accepted by physicians, patients and 
third party payers, and have served as prototypes for the provision of 
clinical pharmacy services. Through cost/effectiveness studies, this 
group persuaded Blue Cross of Ohio and other third party payers to 
reimburse for nondistributive functions on a fee-for-service basis. 
Such successes lend credibility to the concept that pharmaceutical 
services are not necessarily dependent on dispensing, and to the 
viability of clinical pharmacy activities as an integral part of future 
pharmaceutical services . 
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Outpatient IV antibiotic therapy usage is increasint;. H.::..llia11s e t 
al. reported the results of a project where patients with bone or joint 
infections who required prolonged hospitalization were tauGht the use 
and aseptic maintenance of IV equipr.Jent, recognition of sepsis at 
catheter sites, problem solving, etc., and were provided with the 
necessary medication and equipment to be used at horne. The projec t was 
considered safe as well as cost/effective (63). 
Home total parenteral nutrition ( HTPin is one clinical pharmacy 
service that has led to a great deal of savings in health care costs. 
Patients with gastrointestinal disease who had to be hospitalized for 
nutritional support, can now receive therapy in their own homes using 
nighttime feeding schedules; most patients can be mobile and continue 
their daily work (64). HTPN also enhances the qualit y of care and 
inherently reduces the risk of stubborn nosocomial infections (60) . 
Family Practice Clinics. Hany family practice clinics provide an 
intermediary setting connecting hospital-based ambulatory services and 
true community-based ambulatory services. The University of Iowa Family 
Practice Program developed the role of clinical pharmacists engaging in 
patient services frof.l a community base (30,64-66) . Pharmacists in t hese 
settings evaluate medication histories, provide patient education, 
monitor drug therapy, consult with physicians, and assist in overall 
team communication. Brown and Helling reported that during these team 
activities, physicians implemented 96% of the recommendations made by 
pharmacists regarding the care of the patients (64). 
The team approach in the delivery of primary health services was 
dominant in most of the above programs. This type of approach has paved 
the way for the proliferation of clinical pharmacy services as an 
independent co~nunity-based function of pharmacy by demonstrating the 
impact of such services on improving health delivery systems. It is 
also noteworthy that pharmacists in many of these family practice 
programs are reimbursed for the nondistributive services they provide. 
This has becoce acceptable to patients and third-party payers alike 
mainly because clinical pharmacy participation in health care delivery 
has proved its value in curtailing the cost of heal th care and in 
i mproving drug utilization (67,68). 
Cownunity-based Ambulatory Care. In 1984, Schlegel cormnented on 
the expansion of clinical pharmacy into the co~unity practice, due to 
the increase of clinically oriented pharmacists who "must now come out 
of splendid institutional isolation and take leadership in t he 
profession to implement clinical pharmacy practice • • • where it has 
grea t potential" (69). 
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The growth of clinical pharmacy in community pharmacies has not 
paralleled its groHth in institutional pharmacies or in hospital 
outpatient pharrnacies . Clinical activities in community practice have 
not gone beyond patient education; counseling on dosage regi~ens, 
compliance, adverse drug effects ; detection of drug interactions; blood 
pressure monitoring , diabetes testing ; and screening for colon cancer . 
These are possible only in cases where medication records and drug 
histories are kept. 
One example in this area was embarked upon in 1969 at the Ross 
Valley Hedical Clinic Pharmacy in California by Lofholm ( 70) • In this 
integrated medical practice group, the pharmacists provide patient 
education; counseling; chronic disease management, individualization of 
therapeutic r egimens, pre- surgery education and counseling, and ot her 
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activities carried out in consultations with physicians under a protocol. 
Some pharmacists have also established counselinG/consultant types 
of offices, independent of a pharmacy setting, where they provide 
clinical services upon request (71). These consultant services include 
patient education, coordination and monitoring of all prescription and 
over-the-counter drugs taken by the patient, and checking for drug 
interactions. 
Pharmacokinetic Consultation and Pharmacokinetic Surveillance. 
Pharmacokinetic consultation with physicians and pharmacokinetic 
monitoring of patients are professional activities that require 
scientific knowledge, skill, experience, judgment and decision-making 
for which clinical pharmacists are prepared. It is one that has already 
gained acceptance in institutions as a cost/effective and therapeutically 
important activity. 
The value of pharmacokinetic consultations and routine monitoring 
of serum drug concentrations has been well established for a number of 
drugs such as theophylline, anticonvulsants, antibiotics and 
cardiovascular agents. The value of such pharmacokinetic consultations 
has been well documented in institutions and the demand for their 
performance has grown dramatically over the past few years. 
Involvement of clinical pharmacists in pharmacokinetic monitoring 
in teaching hospitals and institutions has led to acceptance of the 
clinical pharmacist as a vital member of the health team. In 1983 
Mungall, et al. reported the impact of clinical pharmacokinetics on 
patient outcome (72). Reduction of inappropriate serum drugs 
concentrations with subsequent reduction of health costs as a result of 
pharmacokinetic consulations in institutions are abundant in the 
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literature (73-75). 
Although institutional pharmacokinetic consultation has been 
increasing, it has not expanded at a parallel rate into the community 
practice. The few examples published demonstrate the need for such a 
service. In 1984 Robinson et al. published guidelines on estabishing a 
pharmacokinetic consultation service for ambulatory patients which 
identifies the need for such a service. In this work serum drug 
analysis was a vital component needed for reimbursement purposes (76). 
Health-Care Costs 
Much has been said about the escalating cost of health care. It is 
a major concern of government, health administrators, policy-makers, 
business, labor, health-care providers and recipients alike. This is 
natural, since the federal, state, and local government pay over 40% of 
the nation's health care costs (77). Resources for health care are 
finite, therefore the problem has led to the realization that both 
short-term and long-term measures of cost containment must be enacted . 
Long-term approaches require biomedical breakthroughs and/or major 
changes in life style, neither of which is likely to be forthcoming soon 
(78). However, some short term measures have already been enacted, 
e.g., the implementation of prospective methods of payment for Medicare 
(Diagnosis Related Groups [DRGs]) and the prospect for their adaptation 
by other third-party payers, the advent and proliferation of Health 
Maintenance Organizations (HMO), hospital rate settings in some states, 
etc. 
Total health care expenditures are escalating at the rate of $50 
billion a year and the per capita per year expenditure was estimated to 
reach $1500 annually for the fiscal year 1984 (78). Overall annual 
health- car e cos ts will increase from $247 billion i n 1980 to t 690 
billion by the year 1990 and to $1. 9 trillion by the end of the 
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century. The r elative share of hea lth-care costs is also expected to go 
from 10% of the gross national product in 1980 to an estimated 14% by 
the year 2000 (77,79). 
The per capita per year health-care expenditure in t his countr y is 
~ore than three tioes t hat in Great Britain or Japar. , and over 
one-and-a-half times that i n France or Hest Ger many (7 8). Huch debate 
has centered on the quality and l evel of health care provided in this 
country as compared to that provided by other highly developed 
countries. Critics and public health advocates contend t hat not enough 
of the health dollar is being spent on disease prevention, chronic 
illness or the care of the elderly. Rather, too much is s pent on 
infrequently used highly technological equipment. Finally, they also 
contend that the current system merely rewards the medical decision-
makers. Proponents of high technology point out the i mprovement in 
acute health care that such high technology brings about and its impact 
on overall health care in general (77). 
Pharmacy's Rol e . The issue of high technology and expensive 
diagnostic equipment is one that concerns pharmacy and influences its 
future. Clinical pharmacy services and innovations, particularly 
sophisticated tertiary level care services, are considered advanced 
technology along with other medical advances. Expenditures of 
health-care revenues and resources on expensive medical equipment and 
technology erodes pharmacy' s share of such resources l eaving less for 
future innovations. Hith financial decision-mal<:ing great ly influenced 
by physicians, clinical pharmacy innovations face difficul t competition. 
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All this has led to an exacination of existing medical programs and 
all new technologies from a cost-effectiveness and health and social 
benefit standpoint (38). It is the opinion of some that future cedical 
innovations must be cost-justified (80,81). 
Indeed , the trend towards cos t jus tification and accountability is 
so stronG that it has even been suggested to initiate intra-professional 
differentiation and priorities in introducing new technologies, services 
or modalities of health care. In the words of Boatman et al. , "One 
recommendation is that Pharmacy as a whole should beGin exacining and 
developing priorities Hith regard to pharmaceutical service innovations, 
in order to successfully compete in an organized frameHork for the 
available resources. We must make decisions within our oHn profession 
as to which service and programs are likely to be roost beneficial 
relative to incurred costs" (38). This is to say that pharmacists must 
compete for the limited health-care dollar, e . g ., an ambulatory 
pharmacokinetic service must be abl e to compete with less sophisticated 
methods of drug therapy monitoring and justify its costs (38). The same 
type of competition Hill face the introduction of neH medical 
technologies and services , keeping in mind that the publ ic (and by 
inference third-party payers also) usually hold physicians less 
cost-accountabl e than they do pharmacists. 
The recent implementation of prospective prici ng systems, with the 
prospect of adoption by insurance companies, is an opportunity for 
clinical pharmacy . In contrast to cost-reimbursement, this system 
encourages hospital administrators to find ways to reduce costs . This 
might be accomplished either through minimizing hospitalization and 
other services or alternatively through expl oring new means and 
1S 
i~novations th~t do not coD~ro~ise the quality of care . ~ospi tal 
pharillaci~ ts can he l p administra tors ninicize costs whil e respondin~ to 
t he concer n of physician3 for hiGh quality care . Such objectives can ~e 
accouplished tl1rou~h dru~-use r eviews, prescribin~ restrictions , 
pharmacists ' product selection preroGatives , etc. (23, n2) . I!ore 
sophisticated drus t he r apy ~onitorinc and pnar~acol~inctic surveillance 
~ay further hel p reduce costs t hrouch t he elimination of inappropriate 
seruQ druG assays , the use of optimal individualized dosase reci uens, a 
reduction in physician and emer e ency room vis its , and perhaps throuch 
the overall reduction in the nureber and duration of hospita l admissions 
(33- 86 ). llew innovative and creative clinical pharmacy services that 
are cost-effective and l ead to overall reduction in health car e costs 
will now have added incentives for i mplementation and undoubtedly a 
Greater chance of success . 
Prospective systems of payment and closer scrutiny over health care 
costs will most likely promote clinical pharmacy. The beneficial 
returns from any health-care program modality, as compared to costs, 
have become an issue of great concern. 
Cost/Benefit and Cost/Effectiveness Studies. The risinG cost of 
health care has emphasized the value of cost/justification very 
clearly . Cost/benefit and cost/effectiveness analyses have become an 
integral part of t he study of clinical pharmacy innovations and 
services . These analyses are also key factors in gaining acceptance 
from the health-care sector in institutional or other settinGs . It 
certainly is a crucial factor in third- party reimbursement 
considerations (38,39 , 41 , 44,45) . 
Cost/benefit analysis (CBA) has been applied to the health care 
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field since the early part of this century (38) . It is 2 practical way 
of evaluatin{.; the desirability of a project or pro.:;ran, takin.:; into 
considera tion all costs incurred and benefits , Quantification can be 
achieved by converting all benefits and costs into dollars or monetary 
equivalents, However , it is not always so simple to Qeasure, quantify, 
or ass i Gn a nonctary value to s uch intangi ble benefits as patient 
comfort, sense of well being or psychosociologica l satis faction. 
A cowplernentary evaluation technique to CBA is cost/effectiveness 
analysis (CEA). Cost/effectiveness analysis is a technique which allows 
for the choice of a specific procedure or method among other alternatives 
that achieves the predetermined outcome objectives, In selecting the 
optimal method or procedure among other alternatives, cost is not always 
t he only constraint. Additionally, it ~ust satisfy the achievement of a 
specific set of results. 
Both CBA and CEA have been used in evaluating health-care programs , 
and in r ecent years in the assessment of clinical pharmacy services. 
Both techniques are valuable and could be applied equally well to the 
evaluation of health care or clinical pharmacy services. However , CEA 
is more applicable in institutions where the program outcomes can best 
be measured in terms of health improvements (86). 
Over the past decade, a number of studies have attempted to apply 
the rigid analytical tools of CBA or CEA to clinical pharmacy services. 
Bootman et al. (85) presented an example of this type of analysis in 
their report on the individualization of gentamycin dosage regimens in 
hospitalized burn patients. In this retrospective cohort study desiGn, 
the impact of a clinical pharmacokinetic service was measured . Specific 
direct benefits compared to the controls included the l ength of 
v 
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hospitalization, length of infection, number of septic episodes, and the 
number of adverse drug reactions. l1ultivariate statistical techniques 
and discriminant analysis were used to measure the impact of the 
pharmacokinetic service . The study covered a four-year period and used 
mathenatical formulae to determine the cost/benefit of the service . 
The greatest benefit came from reducing mortality rates (which vrent 
down from 66% to 36%). A comparison of length of infection ran contrary 
to the expectation that pharmacokinetic surveillance reduces hospital 
stay and length of infection. The authors explained this latter 
observation with the hypothesis that the increased probability of 
survival among patients served increased the ratio of seriously ill 
patients among the kinetic group versus the nonkinetic group, which 
ultimately increased the length of stay and length of infection. For 
this reason, mortality costs were considered as a cost added to the cost 
of the pharmacokinetic service in evaluating the two groups. The 
cost-benefit ratio was 8.7/1. The authors state : " •• this work set 
to bridge the gap between the theoretical discussions of cost- benefit 
analysis and its practical application to evaluating clinical pharmacy 
services." Bootman and his group have also carried out a cost analysis 
for the individualization of dosage r eg imen for the aminoglycoside group 
of antibiotics (87). 
The Ohio State University Hospital Pharmacy Department has also 
carried out CBA and CEA studies on its home health services, as 
mentioned in more detail earlier, and through such studies has secured 
third-party reimbursement for these services (45). 
Chrischilles and coworkers (88) have carried out a CBA study of 
clinical pharmacis t involvement in a hypothe tical single-physician 
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raci l y practice office ano a ~rou~ fa~ily pr act ice office . They have 
shown that such involve~ent is beneficial even in the solo- physician 
fa~ily practic e if a dis~ensin~ co~ponent is i ncorpor ated to suppor t a 
fu ll tir:1e clinica l phar r.Jacis t . 
Levin and his c roup have carried out CEA studi es in t he area of 
cl i nical pharuacy c onsultations in the use of seruo dru~ assays i n a 
U!1i versi t y- affiliated cor.2uunity hospita l ( 73). Their studies shoHcd a 
s i gnificant reduction in the usc of inappropri ate serum druc assays and 
considerable savings in patient char~es . Elcnbass and COI/Orkers ( 33) 
have a l so carried out siuilar studies lli th results that paral l e l those 
of Levin. 
The increasinB fruJiliarity of pharmacists with CBA and CEA 
techniques will allow the appl ication of these valuable tools i n both 
existing and neH innovative clinical pharrJacy services . One nay 
hypothes ize that the result of such applications will further docu~ent 
the positive cost/benefit and cost/effectiveness values of clinical 
pharmacy . 
Pharmacoldnetic r:10ni to ring and consultations are e~:arnples of future 
trends in consultative pharmaceutical activities . Further mor e , the 
application of clinical pharmacokinetic principles is one ac tivi ty that 
shows the potential for directly affectin~ patient outcome Hith respect 
to therapy (73). Acute care settinGs have already validated these 
consul tative activities . Community phar!:lacists providing ambulatory 
care will be increasingly involved in such consultations and hold a large 
share of that future. This work is a modest contribution to that end . 
Whv Theophyll i ne 
For nearly six decades theophylline has been prescribed as a 
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bronchodilator , diuretic, and respiratory stimulant. However , its use 
has also been associated with various reports of adverse side effects . 
The incidence and severity of some of these adverse effects, e.g., 
gastric or CUS effects, can usually be reduced with a reduction of 
dose, Despite that, theophylline is a commonly used therapeutic agent 
in the mana~ement of a variety of both chronic and acute pulmonary 
diseases. 
A great deal of work has been done in exploring the pharmacodynanic 
and pharmacokinetic properties of theophylline. Definition of its 
population pharmacokinetic parameters has increased the safety and 
efficacy of theophylline therapy. It has been determined that a plasma 
concentration of 5-20 mg/liter is necessary for a therapeutic reduction 
of pulmonary vascular resistance with an improved ventilation/perfusion 
ratio. The bronchodilator effect of theophylline is proportional to the 
logarithm of serum concentration over the range of 5-20 mg/liter 
(89,90). It has also been determined that theophylline has a narrow 
therapeutic window of 10-20 mg/liter, requiring extreme care in dosing 
new patients and close supervision of maintenance therapy. 
In 1974, Weinberger and Bronsky demonstrated the usefulness of 
theophylline in preventing symptoms of chronic asthma when serum 
concentrations are continually maintained within the 10-20 mg/liter 
range (91). 
In 1975, Swillich et al. reported their observations on the effect 
of serum theophylline concentrations on the therapeutic and/or toxic 
effec ts of the drug. Eight patients with mean serum theophylline 
concentrations of 54 mg/liter developed severe seizures, resulting in 
death. Patients with serum theophylline concentrations of 35 mg/liter 
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shm·reG. :-::inor adverse effects 1-:nil e oti1ers Hi t h a seru1,; concentra tion of 
19 u:;/li ter shoHed no sic;ns of to;:ici ty. Lost note\lorthy of' the ir 
ob!3ervations was the a~parent absence of ~inor sitie e~fects in seven 
patients prior to the onset of severe se i zur es . Ti1e r.:ec:1ani s: .. of these 
severe toxic reactions has not yet been elucid ated. However, the r e have 
been su3cestions of ce r ebr a l vasoconstriction and hypo::ia, and evidence 
of brain ano~ia an~ neuronal loss has been found at auto~sy (92) . This 
indicates the r eliability of seruu theophylline measures to forewarn the 
physician of inpending toxicity or life- threatenin~ situations, rather 
than depending on clinical s i 6ns and syoptocs. 
Hhen theophylline is used as a bronchodilator in emerGe nc i es or 
acute situations , the coal is to achieve a rapid therapeutic serum 
concentration such t ha t syoptoos are relieved \lith as little delay as 
possible . This goal is best accomplished either throuzh an intravenous 
loadinG dose (93 , 94), or through some rapidly absorbed formulation s uch 
as an oral solution, a plain uncoat ed tablet or a rectal solution if the 
patient is at home or hospitalized with less severe symptoms (93) . 
In 1973 , Hitenko and OGilVie described (89) an intravenous 
theophylline dosage rebimen ba sed on pharQacol~inetic principles . They 
recon~ended a loading dose of 5.6 mGIKG of aminophylline to be followed 
by a 0. 9 nGIKGihr infusion. This reGimen was r apidly adapted at ma jor 
medical centers across the country , only to be followed by subsequent 
reports of theophylline- induped seizures in some patients treated with 
the recoornended regi men 1 \-lhich led to death. Again, r;linor s ymptoms of 
theophylline toxicity such as nausea and vomiting failed to provide 
warning signs prior to seizures in most of the patients (92 , 95) . 
In 1978 , Hendeles and WeinberGer, in an attempt to expl ain the 
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discrepancy betHeen the initial prediction of ~:itenko and Oc:;l ive and its 
disastrous afterQath, sucGested that it mi ght have been because of their 
small, nonrepresentative sample of patients with raean clearance rates 
twice as r apid as subsequently documented for nonsmo l~inc , otherwise 
healthy adults. Other studies have verified this large interpatient 
variability of clearance • In one study, 16 volunteer as t huatics were 
.;iven an infusion of theophylline at the rate of 0. 9 r:~g/Kg/hr and their 
resulting serum theophylline concentrations ranged fro~ 13 to 49 
mg/liter (96 ). A recommendation for a new se t of infusion rates tal~ing 
into account interpatient variability was addressed to the FDA by 
Hendeles in tiovember 1976 (97). Four years later the FD A adopted these 
recommendations which were eventually published in 1980 (98) . (See 
Appendix 1). 
The maximum aminophylline infusion rate i s 25 I;Jg/minute for loading 
doses with maintenance infusion at a much slower rate dependent upon 
patient population. Rapid infusions may produce dizziness , fainting , 
light-headedness, palpitation, syncope, precordial pain, flushing , 
profound bradycardia, premature ventricular contractions, severe 
hypotension, or cardiac arrest. These effects are attributed to the 
sudden high serum concentration which does not allow time for tissue 
adaptation (94,95). 
The goal of achieving therapeutic serum levels can be reached by 
estimating clearance in the individual patients as early as possible in 
the course of treatment utilizing a minimum number of serum theophylline 
determinations (99) . Empirical nomograms for individualized dosing have 
been used in many centers (100-102) and various mathematical models have 
been devised for describing the time course of theophylline concentrat ions 
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in intravenous therapy. The use of computers and hand-held calculators 
progra~ed with these mathematical models has facilitated greatly the 
prediction of steady-state theophylline levels including the early 
stages (pre-steady state) in the course of treatment (103,104). 
Even with the definition of its pharmacokinetic parameters and the 
therapeutic window, individual variations appear to be more pronounced 
with theophylline than with many other drugs. A five-fold range of 
theophylline dosing has been found to be operative in attaining optimal 
therapeutic effects. Ginchansky and Weinberger, in 1977, reported a 
similar range for children, which was due to variations in the rate of 
hepatic biotransformation (105). Hendeles reported similar 
observations, where theophylline toxicity as a result of excessive serum 
levels were associated with the use of recommended dosage regimens , in 
patients with active liver disease or heart failure. Thus, the 
attainment of optimal efficacy, while assuring safety, requires a 
clinical titration of theophylline dosage guided by serum concentration 
monitoring (106). 
In the absence of serum drug monitoring, theophylline dosage would 
have to be kept at low levels to avoid toxicity. This would result in 
the majority of patients having serum theophylline concentrations below 
the therapeutic range (106). Without serum drug monitoring , the 
recommended dosage regimen for theophylline is 400 mg per day in divided 
doses to be increased by not more than 25% of this initial dose at three 
day intervals until therapeutic and/or toxic effects are observed. 
Sampling Time. Blood samples obtained for theophylline level 
measurements in long term therapy are best collected during steady state 
conditions. Patients must comply with the following: no dose missed in 
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the previous 48 hours, no extra doses t aken , and approximately equal 
intervals between doses (91). Strict compliance with the prescribed 
reGimen must be assured through careful interview and medication history 
and further r einforced through counseling. Patients mus t be aware of 
the consequences of improper dosing on serum theophylline measurements. 
In ambulatory patients , low or incons i s t ent serum drug l evel s may not be 
considered as valid or an index of steady-st a t e conditions. The exact 
t ime to collect a blood sample varies with the nature of the theophylline 
preparation and its dosage form. Generally speaking , two hours 
post-dose samples are appropriate for oral solutions or plain non-coated 
tablets with rapid dissolution characteristics. On the other hand , four 
hours post-dose samples are more advisable with most s low release 
preparations. Sampl es obtained 3-7 hours after a dose of Theo-DurR or 
SustaireR are accept abl e because of the slower and more constant 
absorption of these produc ts ( 106). 
Because of diurnal variations in theophylline absorption, blood 
sampl es s hould be collected during the same dosing interval on each 
occasion (106). Following the establishment of the dosage r egimen that 
maintains serum concentra tions within the therapeutic r a nge , further 
monitoring of serum theophylline levels need be done only once a year . 
This i s justifiable since cl ear ance rates , serum l evels and dosing 
requirement s normally remain s table for extended periods of time 
(107-109) . However , normal growth in childr en may result in lower-than-
effective doses and repeated measurements may be required as often as 
every six months during periods of rapid growth (105). Changes in 
environment, pathophysiology or concurrent drug therapy ( e . g ., addition 
of cimetidine , smoking habits, abnormal die tar y changes, proloneed 
febrile states, alterations in liver or cardiac functions) influence 
drug elicination and Harrant more frequent reassessment of serum 
theophylline concentrations (109). 
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Theophylline Formul ations . As the therapeutic use of theophylline 
has gained popularity in the past few decades, pharmaceutical 
manufacturing firms marketed a variety of theophylline formulations and 
products. However, not all of these products have proven their worth in 
clinical practice (106). 
Because it is a therapeutic agent that was available before the 
1938 Food, Drug and Cosmetic Ac t, theophylline reformulations do not 
require FDA approval prior to marketing. This has led t o t he 
introduction of a number of preparations that are either not 
efficacious, do not live up to manufacturers' claims, or offer no 
advant age over formerly available agents . On the basis of 
post-marketing surveillance data, the FDA has approved some sustained-
release products: LaBidR, Somophylline-RTR, SustaireR and Theo-DurR. 
FDA approval of a particular sustained-release formulat ion 
indicates that multiple, individually adjusted doses given to adults 
every 12 hours will usually provide steady s tate serum theophylline 
concentrations in the range of 10-20 mg/liter. Unfortunately the FDA 
regulations require that the adult test population be composed of 
nonsmokers (mean half-life range 8 hours versus 4.5 hours for smokers). 
Obviously, products that are capable of maintaining therapeutic serum 
theophylline levels with 12-hour dosing intervals in this patient 
population may not do so in faster metabolizers. 
In order to achieve the greatest likelihood of maximum benefit from 
theophylline therapy for chronic asthma , serum concentrations should be 
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maintained within the therapeutic range around the clock. Fluctuations 
in serum concentrations, i . e. , the difference between peak and trough 
concentrations expressed as a percentage of the trough, are a function 
of the rate of absorption of the product , the patient's theophylline 
elimination rate and the dosing interval (107) . Since the width of the 
therapeutic range is only 10 mg/liter, fluctuations must be less than 
100% to maintain the serum level within the therapeutic range throughout 
each dosing interval. 
Slow eliminators, infants of less than six months, and about 25% of 
nonsmoking adults experience small fluctuations--considerably less than 
100%--when they are given rapid-release formulations every eibht hours . 
Nevertheless , slow-release products administered every 12 hours offer 
greater convenience for these patients and yet produce t he same degree 
of fluct~ation as the rapid-release formulations taken every 8 hours. 
It appears that differences in rates of absorption among the various 
sustained-release products bear little clinical significance in slow 
eliminators (106) . 
In children, adult smokers, and about 25% of nonsmoking adults, 
theophylline elimination is sufficiently rapid to cause excessive 
fluctuations in serum concentrations in between doses of rapid-release 
formulations even if dosing intervals are shortened to six hours 
(107). Sustained-release formulations provide significantly better 
control of symptoms than rapid-release formulations . Additionally , 
compliance with drug therapy is improved markedly with products that 
allow for a twice-daily regimen (110,111). 
Hendeles and Weinberger reported that three sustained-release 
preparations, SlobidR , SustaireR and Theo-DurR , are completely absorbed 
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but with such a s l ow rate that it allows for the maintenance of 
therapeutic serum l evels in rapid eliminators given every twelve hours 
( 106). It should be r emembered, however , that even with these products 
some patients require dosing every eight hours to avoid repeated 
breakthroue hs of asthmatic symptoms , particul arl y t hose wi th high dosage 
requirements due to very rapid elimination (110 , 111) . Other sustained-
re l ease products require eight- hour dosinti intervals, despite manufac-
turers ' claims , in order to prevent serum concentration fluctuations of 
greater than 100% in rapid eliminators (106). 
GOALS AIID OBJECTIVES 
Goals 
The goal s for this work were: 
1. To develop a model for a pharmacokinetic service for ambulatory 
patients in a community setting as a home health service usinG 
theophyl l ine as a prototype. 
2. To determine the impact of community- based pharmacokinetic 
services on: 
a. The health status of the patient population served . 
b. The costs incurred by the service. 
3. To determine if the service is cost-beneficial. 
Objectives 
The objectives of this work were : 
1. To design and define components of a community-based 
pharmacokinetic consultation service for theophyl line therapy. 
2. To define criteria for selection of patient populations. 
3. To develop a procedure for monitoring theophylline therapy for 
patients with chronic asthma and/or COPD . 
4. To determine the impact of such a community-based 
pharmacokinetic consultation service on: 
a. Frequency of ordering serum theophylline level 
measurements . 
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b. Frequency of ordering inappropriate serum theophylline 
l evel measurements. 
c. Number of physician office visits. 
d. Number of days of hospitalization secondary to pulmonary 
problems. 
e. t~umber of emergency room visits secondary to pul monary 
problems. 
5. To calculate the cost of the service. 
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6. To determine if any benefits are gained from the service by the 
patient population receiving the service, i.e., the experimental group. 
7. To determine the level of acceptance of the service by the 
participating physicians, by calculating the percentage of 
recommendations made by the clinical pharmacist that were accepted by 
the physicians. 
8. Subjectively assess the level of acceptance of the service by 
the patients . 
l1ETHODOLOGY 
General Description 
The clinical pharmacokine tic service was designed as a hone health 
care alternative for patients with chronic asthma and/or COPD r eceiving 
theophylline therapy for six months or longer. 
Patients vrere referred to the study by f amily practice physicians 
in private practice. Upon referral, the patients vrere assigned randomly 
to experimental or control groups . The experimental group rece ived the 
service for six months. 
One of the unique aspects of this study was that i t was provided by 
the clinical pharmacist at the patient's residence. The clinical 
pharmacist was to initiate or continue theophylline therapy in the 
experimental group. The pharmacist vras to monitor the patient therapy 
through the entire period of the study, order serum blood l evel 
measurements when appropriate, and suggest alterations of therapy to 
attending physicians, if so indicated. 
Components of the Community-Based 
Clinica l Pharmacokinetic Service 
The clinical pharmacokinetic service for the experimental group 
consisted of the following components: 
1. Chart review. Upon referral by the attending physician, the 
clinical pharmacist performed a chart review for each patient to compile 
a data base. Patients were considered smokers if they had a history of 
smoking nine months prior to referral to the study. 
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2. Home visitations. Once a month, during the six-month period of 
the study, the clinical pharmacist visited each patient at his/her home 
to assess the patient and provide medication education. During these 
home visits, the pharmacist performed the followins : 
a. Assessment of blood pressure, pulse and respiration. 
b. Assessment of pul monary function with the aid of a 
hand-held spirometer.a 
c. Perform auscultation of lung sounds. 
d. Interview the patient for the purpose of i dentifying 
drug-related problems. 
e. Counsel the patient to ensure compliance. 
f. Educate the patient on his/her therapy, drug interactions 
and compliance. 
3. Pharmacist-physician consultation. When indic ated, the 
pharmacist consulted with the attending physicians regar ding t heir 
patients' therapy and made specific recommendations related to: 
a. Dosage and dosing interval. 
b. Alternative medications. 
c. Adverse drug reactions and drug interactions. 
d. Recommendations for theophylline serum level 
determinations . 
e. Communication of relevant pharmacokinetic information 
obtained from calculations based on specific patient parameters, serum 
theophylline levels and standard pharmacokinetic formulae. 
aHand-held Buhl Spirometer, Hodel 113791 , Graham-Field Surgical Co ., 
Inc., 415 2nd Avenue, New Hyde Park, New York 10040 . 
Identificatior. of Pctient 
Populations 
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Patients were admitted to the experimental study group if they met 
the following inclusion criteria: 
1. A diag nosis of chronic obstructive pulmonary disease and/or 
bronchospasm or asthma. 
2. Therapy with theophylline, or other theophylline products, for 
six months or more. 
3. Referral to the study by attending physicians. 
4. \·iillingness to provide informed consent . 
Patients were excluded from the study if they were under seven years of 
age, mentally disabled, had a terminal prognosis (i . e . , less than s i x 
months life expectancy), or resided more than thirty miles from the 
greater Stockton metropolitan area. The same criteria were applied to 
the control groups except for the written consent provision. 
Patient Populations 
Experimental Group. A total of seventeen ambulatory patients under 
the care of family practice physicia ns in private practice were assigned 
randomly to the experimental group and received the clinical 
pharmacokinetic service for six months . 
Control Groups. Three control groups were included in the overall 
evaluation of the clinical pharmacokinetic service . These were: 
1. Concurrent office control. A total of seventeen patients were 
randomly assigned to the concurrent office control group . These 
patients were under the care of the same attending family practice 
physicians as the experimental group. 
2 . Concurrent clinic control . Seventeen patients under the care 
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of the "Family Practice Clinic" at San Joaquin General Hospital were 
randomly assicned to the concurrent clinic control group. These 
patients were under the care of family practice physicians otner than 
those of the experimental or concurrent office control. It was deemed 
to be advantageous to have such a control group in order to neutralize 
or avoid any possible overspill effects that the mode of treatment of 
the experimental group might have on treat~ent modalities of the office 
control group. 
3. Retrospective office control. This group is the same as the 
experimental group. The past medical histories of these patients were 
evaluated as a retrospective control. Tables 11 2, and 3 represent the 
demographic data for the different groups. 
Statistical Analvsis 
Several methods of statistical analysis were used to detect the 
significance of differences among the means, at a probability level less 
than 0.05: 
1. A one- way analysis of variance was used to determine whether 
there was a significant difference in the variables studied between the 
groups in the study (Tables 4- 9 and 18-22). A post-hoc test based upon 
the F distribution \'las used to examine differences in mean values 
between any two groups. 
2 . Student test (t) was used to determine whether there was a 
significant difference between two groups when applicable (Tables 7 and 
21 ) • 
3. The T method for the presence of outliers Has performed to 
detect the significance of differences in testing of the precision of 
the spirometer (Tables 11-13) (112) . 
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The correlation coefficient (r) was calculated to examine the level 
of correlation between the change in lung volumes and the change in 
plasma theophylline concentration. 
Comparison of t he Control Groups 
To ascertain the validity of the control groups used in the study , 
chart review was performed on al l members of the control groups for a 
period of 12 months . 
The variables studied were the following : 
1. Number of visits to physicians ' office. 
2 . lJumber of serum theophylline concentration deterrr.inat ions. 
3. Number of inappropriate theophylline serum concentration 
determinations. Samples v1ere cons idered inappropriate if: 
a . There was no indication of the sampling time . 
b. Sampling time vtas indicated but was inappropriate for a 
particular dosage form. 
Samples \,•ere not cited for lack of documentation of steady state , 
misinterpretation, or lack of action in case of subtherapeutic l evel s . 
4 . Number of emergency room visits due to pul monary exacerbat ions . 
5 . Number of hospital admissions . 
6. Number of days of hospitalization. 
Tabl es 4- 9 show the data collected, means , and s tandard deviations 
of the means . Analysis of variance was carried out on each data set to 
determine the significance of any differences that existed . 
Dosaee Forms 
Patients accepted into the study were either on Aminophylline 100, 
200, or 300 mgs , or on Theo-DurR 200-500 mg, both in tablet form. For 
the experimental group, however , the clinical pharmacist suggested 
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chanGes to the sustained-release Tneo- DurR tablets , to ensure patient 
compliance and/or avoid theophylline serum level fluctuations normally 
associated with Aminophylline tablets (106) , 
Pharmacokine tic Procedures 
Standard pharmacokinetic parameters documented in the literature 
such as average volume of distribution for theophylline, average half 
life and elimination rate constant at steady state ( 106 ) Here used to 
dete rmine the dosage regimens. 
Serum theophylline levels were ordered as a moni toring t ool and a 
guide for dose adjustments, Laboratory orders Here initiated by the 
clinical pharmacist after consultation with attending physicians, Serum 
theophylline determinations were performed at the same laboratories used 
by patients before the study to ensure uniformity, All serum 
theophylline concentration determinations were carried out at steady 
state, Patients were made aware of the importance of steady state 
determinations and the critical issue of sampling time . 
As a general rule, three hours post dose was considered the optimum 
time for serum theophylline determinations for patients r eceiving 
aminophylline tablets, On the other hand, five hours post dose was 
considered the optimum time for serum theophylline determinations for 
patients receiving Theo-DurR tablets (106). 
The pocket-sized HP 41-CV Programmable Calculatora was used in al l 
calculations . The "multi K" program (113) feature was utilized for 
calculations . In this program the volume of distribution is fixed at a 
reported value of 0.5 L/ Kg of total body weight and ca lculations were 
aHP-4 1 CV Programmable Calculator, HEHLETT-PACKARD 1000 N. E. Circle 
Blvd ,, Corvallis , OR 97330. 
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then made accordin;ly. After the first serum theophylline measurement , 
a second serum level can be predicted at a l ater time by seeding a 
reported elimination rate cons tant for the individual patient's age 
3r oup. Vith the availability of two serum theophylline l evels, the 
elimination rate constant for the individual patient can then be 
cal culated. 3ased upon the laboratory r esults and t he patients' da ta, 
the clinical pharr.mcist calculated the optir:lal dose for each patient and 
the appropriate doseibe r egi men , •rhich Has reported to the physician for 
approval. 
Assessment of Pulmonary 
Functions 
Test of precision of the spirometer. The spirometer was tes ted 
monthly using six healthy volunteers of different age sroups . Each 
month for six months the Forced Vital Capacity (FVC) and Forced 
Expiratory Volume in one second ( FEV1) for these healthy volunteer s wer e 
determined using three measurements for each volune. The aver age of 
these values i s r eported in Tabl es 10-13 . The T me thod f or the presence 
of outlier s was performed to determine the s i gnificance of the 
differences among the means for each volunteer during the six month 
period. 
Spirometry. A hand- held s pirometer was used to assess lung volumes . 
Patients in the experimental group Here assessed in this manner during 
each home visit, i.e ., once a month. The clinical pharmacis t explained 
the t est and demonstrated the instrument use . ~~o measurements were 
determined each time : FVC and FEV1 . Each measurement was repeated at 
l east three times and the average was calculated . A hand-held timer was 
used to measure the time interval of one s econd . 
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Table 1~ lists the spiroQetric measurements of seven patients in 
whom intervention in treatment was suggested. The type of intervention 
is also shorm. 
Correlation Between Lung 
Volume Measurements and 
Theophylline Serun Levels 
The change in lung volumes of the seven patients mentioned in 
"Spirometry" was compared to the correspondin;; change in serum 
theophylline levels when applicable. Pre and post intervention levels 
were available for 5 patients only. Tables 15 and 16 list the data and 
the correlation coefficient. 
Phys i cian ' s Response to 
the Clinical Pharmacist 
Recommendations 
Acceptance or re jection by the attending physician of the clinical 
pharmacist's recommendat ion for changes in dosage regimens, appropriate 
timing of serum theophylline level determinations, etc. were recorded 
and the data is s hown in Table 17. 
Cos t/Benefit Analysis of the 
Pharmacokinetic Service 
Direct benefits of the service were calculated in terms of s avings 
per patient . All significant changes in the variable s studied that 
resulted in changes in costs were converted to dollar values using 
current estimates of charges . These included physicians' office visits, 
serum theophylline measurements, hos pitalization, and emergency room 
visits, as shown in Tables 18-22 and 23 . 
The direct costs of the service were calculated in terms of the 
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clinical pharmacist' s time. The followint; components v1ere considered in 
calculating the time: 
1. The actual time spent to review the medical record and 
establish the data base for each patient. 
2 . The time spent with each patient during the initial visit and 
each monthly visit (Table 24) . 
3. Travel time to and frorr: the patient's home using the School of 
Pharmacy as the base of the service; the data i s shown in Table 25. 
All t he time spent by the clinical pharmacist was then converted to 
dollar values by using current pharmaci st \·rages ( 11 4) plus 20% fringe 
benefits. Cost of travel was calculated as a charge of $0 . 205/nile 
traveled (115). Table 26 shows all costs of the service for t he entire 
six months. 
Table 27 summarizes the costs and savings data as well as the 
benefits incur r ed as a result of the service. 
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Table 1. DemoGraphic Data of the Experimental Group 
Patient No. Sex Age Race Di agnosis Smoker Insurance 
F 41 ca coPDb No pC 
2 F 71 c COPD !Jo p 
3 F 20 c Asthma No p 
4 F 47 c Asthma No Hone 
5 N 58 c COPD l~o p 
6 F 71 c COPD t~o p 
7 F 38 c Asthr.Ja No p 
8 t1 61 c Asthma No p 
9 N 15 c COPD No p 
10 11 71 c COPD No p 
11 F 48 c COPD No p 
12 F 47 c COPD No p 
13 F 45 c COPD No p 
14 !•1 12 c Asthna No p 
15 F 38 c Asthma Yes p 
16 N 74 c COPD No p 
17 H 61 c Asthma Yes p 
acaucasian 
bchronic Obstruc tive Pulmonary Disease 
Cprivate 
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Table 2 . De~oGraphic Data of the Concurrent Office Group 
Patient I~o . Sex Age Race Diagnosis Smoker Insurance 
:.j 60 A a coPDd r~o pe 
2 t·1 62 cb COPD lio p 
3 F 40 c Asthma ~ :o p 
4 l·~ 52 A COPD I!o p 
5 F 70 A As t hma No p 
6 11 47 A As t hma flo p 
7 F 64 c COPD !Jo p 
8 N 71 c As t hma No p 
9 F 34 c COPD No p 
10 f.! 72 c Asthma No p 
11 F 49 c Asthma No p 
12 M 56 c Asthma No p 
13 N 65 c COPD No p 
14 t'~ 38 c As t hma ~0 p 
15 11 55 c COPD Uo p 
16 H 68 c COPD No p 
17 F 71 Be COPD No p 
a Asi an 
bcaucasian 
cBl ack 
dchronic Obstruct i ve Pulmonar y Disease 
eprivate 
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Tabl e 3. DecoGraphic Data of the Concurrent Clinic Group 
Patient J-;o . Sex AGe Race Diacnosis Smoker Insurance 
F 41 ca COPDc No t·!e 
2 F 49 c COPD Yes pd 
3 F 47 c Asthma Ho :1 
4 F 29 c Asthma Ho li 
5 H 14 Bb Asthma No l-~ 
6 F 68 c COPD Yes t·: 
7 J.1 60 c COPD No Other 
8 H 67 B COPD No N 
9 F 36 c Asthma Yes l'1 
10 F 37 c Asthma/COPD No p 
11 F 47 c COPD tlo Other 
12 H 64 c Asthma/COPD !Jo p 
13 F 63 c Asthma No H 
14 N 7 B Asthma No ll, 
15 F 59 c COPD Ho 1-1 
16 F 60 c Asthma No t--1 
17 F 60 c COPD No M 
acaucasian 
bBl ack 
cchronic Obstructive Pulmonary Disease 
dprivate 
eNedi- Cal 
Table 4. Co~parison of the Control Groups Based Upon Physici ans ' Office 
Visits . 
Patient Ho . 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
~lean 
S.D. 
NA = Not available 
Retrospective 
Office 
Control 
NA 
12 
11 
2 
11 
11 
5 
6 
8 
NA 
3 
11 
9 
HA 
6 
4 
31 
9.29 
6 .83 
ANOVA = No significant difference 
Time = 12 months 
Concurrent 
Office 
Control 
13 
11 
19 
9 
11 
10 
15 
4 
11 
19 
11 
14 
14 
9 
12 
3 
12 
11 • 59 
4.09 
Concurrent 
Clinic 
Control 
9 
10 
12 
10 
10 
12 
10 
21 
12 
6 
11 
7 
10 
9 
6 
17 
10 
10 . 71 
3 . 58 
·'. 
. :~~l . 
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Table 5. Comparison of the Control Groups Based Upon Theophylline Serum 
Levels. 
Patient No. 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
!-lean 
S.D. 
Retrospective 
Office 
Control 
HA 
!lA 
0 
2 
0 
NA 
0 
0 
3 
2 
0 
4 
1. 14 
1.23 
NA = Not available 
ANOVA - F Value = 5 . 95 and P < 0.05 
Sheffe' value: Significant difference 
control and concurrent 
Time = 12 months 
Concurrent 
Office 
Control 
5 
7 
2 
2 
0 
0 
2 
0 
2 
3 
0 
4 
1.88 
1.93 
between retrospective 
clinic control. 
Concurrent 
Clinic 
Control 
8 
3 
2 
3 
4 
5 
3 
2 
3 
2 
5 
2 
5 
7 
2 
3.41 
2.00 
office 
Tucl c o . ~ o~~a~ison o: t he Control Groups ilasea Upon Inapp~o~riate Lab 
Drdcr~ . 
Patient iio . 
2 
? 
J 
0 
7 
8 
9 
10 
11 
12 
13 
1 !! 
15 
16 
17 
!-lean 
S. D. 
lJA = Not available 
?.e trospective 
Office 
Control 
HA 
0 
2 
0 
0 
HA 
0 
0 
0 
3 
2 
0 
0 
0.71 
0 . 99 
ANOVA - F value = 8 .1 35 and P < 0. 05 
Concurrent 
Office 
Control 
5 
0 
5 
0 
0 
0 
0 
0 
4 
1. 29 
1. 69 
Concurrent 
Clinic 
Control 
2 
3 
4 
5 
2 
2 
0 
4 
2 
3 
5 
2 
2 . 32 
1. 94 
Scheffe ' value: Si gni ficant di fference beti·reen concurrent clinic control 
and concurrent office control . 
Time = 12 months 
Significant difference between concurrent clinic 
control and retrospective office control. 
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Table 7. Comparison of the Control Groups Based Upon Number of 
Emergency Room Visits . 
Retrospective Concurrent Concurrent 
Office Office Clinic 
Patient No. Control Control Control 
0 0 0 
2 0 0 0 
3 0 0 0 
4 0 0 
5 0 0 4 
6 0 0 0 
7 0 0 1 
8 0 0 0 
9 0 0 
10 0 0 
11 0 0 2 
12 0 0 
13 0 0 3 
14 0 0 4 
15 0 0 0 
16 0 0 4 
17 0 0 
He an 0 0 1. 35 
S.D. 0 0 1. 5 
t test, t value = 3 . 68 and P < 0 . 05 
Significant difference between concurrent clinic control and concurrent 
office control. 
Significant difference between concurrent clinic control and retro-
spective office control . 
Time = 12 months 
Table 8. Comparison of the Control Groups nased Upon Days of 
Hospitalization 
Retrospective 
Office 
Patient Ho . Control 
0 
2 0 
3 0 
4 8 
5 10 
6 0 
7 0 
8 0 
9 0 
10 0 
11 0 
12 0 
13 0 
14 0 
15 0 
16 6 
17 0 
t·1ean 1.50 
S. D. 3.31 
ANOVA = No significant difference 
Time = 12 months 
Concurrent 
Office 
Control 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
25 
0 
3 
0 
1. 75 
6.24 
. ""-· .. ·
.r 
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Concurrent 
Clinic 
Control 
14 
0 
0 
0 
60 
7 
3 
3 
3 
0 
0 
0 
6 
12 
3 
0 
0 
6.94 
14.71 
Table 9. Comparison of the Control Groups Based Upon Number of 
Hospital Admissions. 
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Retrospective Concurrent Concurrent 
Patient No . 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
He an 
S. D. 
Office 
Control 
0 
0 
0 
8 
2 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0.7 1 
1.96 
ANOVA = No significant difference 
Time = 12 months 
Of fice 
Control 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0. 24 
0.75 
Clinic 
Control 
0 
0 
0 
20 
0 
0 
0 
2 
4 
0 
0 
1. 88 
4 . 78 
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Table 10. Test of Precision of the Spirometer 
Forced Vital Capacity 
Subject fl 2 3 4 5 6 
2500 5100 3700 3000 3400 4000 
2800 5200 3600 2900 3500 4200 
month .23.QQ 51.QQ .31QQ. .3.QQQ. .32QQ. .3..9.Q.Q. 
mean 2733 5133 3667 2967 3367 4033 
S.D. 208 58 58 58 153 153 
2500 5100 3600 2900 3300 4000 
2800 5200 3600 3000 3200 4100 
month 2 .2.a5Q .5.3.QQ .3l.QQ. .2.9QQ. .32.5Q lli.Q. 
mean 2717 5200 3633 2933 3250 4083 
S.D. 189 100 58 58 50 76 
2600 5100 3700 3000 3500 4000 
2600 5200 3600 2900 3400 4100 
month 3 2.1_QQ .5..2.QQ .3QQQ. .3.Q.QQ .llQQ 3.9.QQ 
mean 2633 5167 3633 2967 3433 4000 
S.D. 58 58 58 58 58 100 
2600 5100 3700 3000 3400 3950 
2600 5100 3700 3000 3300 3900 
month 4 Zl.QQ. .5.3.Q.Q. .3QQQ. .3..Q.Q.Q. lliQ .!UQ.Q. 
mean 2633 5167 3650 3000 3350 4000 
S.D. 71 141 71 0 71 141 
2600 5300 3600 3000 3400 4000 
2700 5200 3700 2900 3200 4100 
month 5 
.2.6.QQ. 5..l.QQ .3QQQ. .3.QQQ. .3.!J..QQ .!IQQQ 
mean 2633 5200 3633 2967 3333 4033 
S.D. 58 100 58 58 115 58 
2700 5100 3700 2900 3200 4000 
2700 5200 3600 3000 3400 3900 
month 6 
.2.aQ.Q. .5.2Q..Q. .3QQQ. .3..Q.Q.Q. .llQ.Q. .!LQQQ 
mean 2733 5167 3633 2967 3367 3856 
S.D. 58 58 58 58 153 58 
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Table 11 . Test of Precision of the Spirome t er 
Forced Vital Capacity 
Subject No, 
!·!onth 2 3 4 5 6 
2733a 5133 3667 2967 3367 4033 
2 2700 5200 3600 3000 3400 3900 
3 2633 5167 3650 3000 3350 4000 
4 2633 5200 3633 2967 3333 4033 
5 2733 5167 3633 2967 3367 3967 
6 2733 5178 3733 2078 3378 3078 
mean 2694 5172 3636 2978 3364 3983 
S.D. 49 25 22 17 22 51 
avalues listed are the means of three determinations in milliliters , 
T test for presence of outliers indicated no signif icant difference 
at P < 0. 05 . 
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Table 12 . Test of Precision of the Spirometer. 
Forced Expiratory Volume in One Second 
Subject f.! 2 3 5 6 
1250 2600 2000 1200 1400 1900 
1300 2700 2000 1200 1400 1800 
month 1lQQ .2QQ.Q. .2lQQ_ .12.QQ .lliQ 2000 
mean 1283 2633 2033 1200 1400 1900 
S.D . 29 58 58 0 0 100 
1300 2500 2100 1150 1400 2000 
1200 2500 2000 1200 1400 1900 
month 2 .135Q ~ 2.Q.QQ .1W.. .1.35Q llQQ 
mean 1283 2533 2033 11 83 1383 1933 
S.D. 76 58 58 29 29 58 
1400 2700 2050 1200 1350 1850 
1300 2600 2000 1200 1400 1900 
month 3 12QQ. .21.QQ. .2.QQQ 1.2QQ. 1.!!QQ. .1.2QQ 
mean 1300 2667 2017 1200 1383 1883 
S.D. 100 58 29 0 29 29 
1250 2700 2100 1150 1400 1950 
1300 2600 2050 1200 1400 1950 
month 4 
..1.35Q Zl.QQ .2QQQ 1Z.QQ lliQ .2.QQQ 
mean 1300 2667 2050 1183 1383 1967 
S.D. 50 58 50 29 29 29 
1300 2700 2000 1250 1350 2000 
1250 2700 2100 1200 1350 1950 
month 5 1.3QQ. .2.QQQ ZQQQ. .1£Q.Q. 1.!!QQ. ZQQQ 
mean 1283 2600 2033 1217 1367 1983 
S.D. 29 404 58 29 29 29 
1300 2600 2000 1200 1400 1950 
1300 2500 2100 1250 1350 1950 
month 6 .1..2.5Q 2.6.QQ 2.1QQ. .1.2..Q.Q. 1.!!QQ. .2.QQQ 
mean 1283 2567 2067 1217 1383 1967 
S.D. 29 58 58 29 29 29 
Tabl e 13 . Test of Precision of the Spirometer 
Forced Expiratory Volune in One Second 
Sub ject llo . 
l~onth 2 ? 
..J ~ 5 
1238a 2633 2033 1200 1400 
2 2383 2533 2033 11 83 1383 
3 1300 2667 2017 1200 1383 
4 1300 2667 2050 11 83 1383 
5 1283 2600 2033 1217 1367 
6 1283 2567 2067 1217 1383 
mean 1288 26 11 2039 1200 1383 
S. D. 9 54 17 15 11 
avalues listed are the means of three determinat ions 
T test of presence of outliers indicat ed no significant differences 
at P < 0. 05 . 
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1900 
1933 
1883 
1967 
1983 
1967 
1939 
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Table 14. Spiro:.1etric Anal ysis - (i;FI:V1 /FVC] 3efore anci After Chanc e 
in Therapy. 
%FEV1 /FVC ~ FEV1/FVC 
before Type of after 
Patient li Intervention Aver ace Intervention Intervention AveraGe 
38 .7oa 36 . 98 increased dose 46 . 95 47.09 
35 .26 !17. 26 
1J8 . 14 
46.04 
2 4!1.54 44.56 increased dose 56.80 56 . 83 
4LI. 85 and DDib 57.80 
4lJ . 30 55 . 90 
3 lJ9.20 )j(l . 50 increased 51.36 53.03 
lJ7 . 80 co:Jpliance 53.50 
53.12 
5lJ. 16 
lj 52.50 52.90 increased dose 62.50 60 . 87 
53 . 30 63 . 25 
53 .55 
6lJ.20 
5 47. 60 47.60 increased dose 54 . 30 55 . 93 
55 . 137 
53.30 
58 . 54 
57.65 
6 45.80 increased dose 68.73 63.86 
66 . 50 
60 . 00 
60 . 80 
63.29 
7 40 . 00 increased dose 51.90 51.61 
and compliance 57.00 
47 . 45 
51 . 00 
50 . 70 
Hean : 45.19 55 . 52 
S. D. . 5.34 5.65 . 
Patients 8-17 - No change i n therapy 
t value = 6. 49 and P < 0.05 
avalue l isted is the mean of three determinations 
bDrug- drug interaction 
Table 15. Average Values of [ ~FEV1/FVC ) and the Corresponding Serum 
Theophylline Levels Before and After Change in Therapy, a 
Before After 
Patient It Intervention Intervention 
55 
%FEV1/FVC Serum Cone, ~FEV1/FVC Serum Cone. 
2 
3 
4 
5 
6 
7 
36.98 
44.56 
48.50 
52.90 
47 . 60 
45 . 80 
40.00 
(mg/L) 
4. 7 47.09 
9.8 56 . 23 
NA 53 . 03 
4. 0 60 .87 
5 . 6 55.93 
9 . 0 63 . 86 
NA 51.61 
apre-intervention theophylline levels were not available for 
patients 3 and 7 . 
( mg/L) 
10. 5 
14.0 
8.4 
8.7 
12 . 0 
18.5 
14.0 
Taj le 16 . Correlation of Chan~e in [%FEV1/FVC ] with Change in Serum 
Concentration. a 
Change In 
Change In Serum Cone . 
Patient <.< %FEV1/FVC rug/L 
10 . 11 5. 8 
2 11.67 4. 2 
4 7.97 4. 7 
5 8.33 6 . 4 
6 18.06 9.5 
Correlation coefficient = 0 . 775 
a pre- intervention theophylline levels were not available for 
pa tients 3 and 7. 
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Table 17. Physicians' Reactions to Pharmacist's Suggestions. 
Humber !~umber of Number of 
of Suggestions Sug;;estions 
Patient Ilo . Suscestions Granted Rejected 
2 2 0 
2 3 3 0 
3 4 4 0 
4 0 
5 0 
6 4 3 
7 3 3 0 
8 3 3 0 
9 2 2 0 
10 2 2 0 
11 2 2 0 
12 2 2 0 
13 3 3 0 
Total 32 30 2 
% of total suggestions 93.75% 6.25% 
aNa interventions Here recommended for patients 14-17. 
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Table 18 . Nu~ber of Physicians ' Visits. 
netrospective Concurrent Concurrent 
Patient Experimental Office Office Clinic 
Number Group Control Control Control 
0 0 7 5 
2 6 6 5 6 
3 5 7 10 6 
4 2 5 5 
5 5 4 5 5 
6 5 7 5 6 
7 3 2 7 4 
8 3 3 2 9 
9 2 4 7 6 
10 0 6 10 3 
11 3 8 7 
12 2 4 6 4 
13 0 5 6 6 
14 5 9 5 4 
15 3 3 6 2 
. 16 2 2 1 6 
17 9 18 6 5 
He an 3 . 059 5.000 5.941 5.235 
S.D . 2.487 4.047 2.304 1.602 
SE!1 0.603 0.981 0. 559 0.389 
Anova: F Value = 3.402 and P < 0.05 
Scheffe Value: Significant difference between experimental group and 
concurrent office control. 
Table 19. Number of Serum Levels Ordered. 
He an 
S.D. 
SEH 
1. 058 
0 .555 
0.134 
ANOVA: No s ignificant difference. 
0. 882 
0 . 809 
0.196 
1 • 176 
1. 235 
0 . 3 
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1. 764 
1.347 
0 . 326 
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Table 20. Hu~ber of Serum Levels Ordered Inappropriately. 
Retrospective Concurrent Concurrent 
Patien t Experimental Office Office Clinic 
Humber Group Control Control Control 
0 0 2 4 
2 0 0 
3 0 2 
4 0 0 0 3 
5 0 0 0 2 
6 0 2 
7 0 2 0 
8 0 0 0 0 
9 0 0 
10 0 0 0 
11 0 0 2 
12 0 0 
13 0 0 0 2 
14 0 2 0 0 
15 0 0 1 4 
16 0 0 0 
17 0 0 4 
He an 0 0.471 0.882 1. 412 
S.D. 0 0 . 717 1 • 111 1.278 
SEH 0 0 . 174 0. 270 0. 310 
ANOVA: F Value = 6. 244 p < 0.05 
Scheffe Value : Si gnificant difference between experimental group and 
concurrent office control. 
Significant difference between experimental group and 
concurrent clinic control . 
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Table 21. Number of Emergency Room Visits Secondary to Pulmonary 
Problems. 
Retrospective Concurrent Concurrent 
Patient 
Humber 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
Nean 
S.D. 
SEM 
Experimental 
Group 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
Office 
Control 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
Office 
Control 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
t test: Significant difference between experimental group and 
concurrent clinical control . 
Clinic 
Control 
0 
0 
3 
0 
0 
0 
0 
1 
0 
0 
3 
0 
0 . 706 
0 . 985 
0 . 239 
62 
Table 22. Number of Days of Hospitalization Secondary to Pulmonary 
Problems. 
Patient 
!:umber 
2 
3 
4 
5 
6 
1 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
He an 
S.D. 
SEt·1 
Experimentc.l 
Group 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
Retrospective 
Office 
Control 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
9 
0 
0 
0.529 
2.183 
0 . 529 
ANOVA : No significant difference. 
Concurrent 
Office 
Control 
0 
0 
0 
4 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
6 
0 . 588 
1.698 
0 . 412 
Concurrent 
Clinic 
Control 
14 
0 
0 
0 
30 
0 
3 
0 
0 
0 
0 
0 
0 
3 
0 
0 
0 
2.941 
7 . 774 
1. 885 
Table 23 . Means of the 5 Different Variables and Their Statistical Analysis.a 
Experimental Retrospective Concurrent Concurrent Sig . Dif , Scheffe 
Variables Group Office Group Office Group Clinic Group p < 0 . 05 Value 
No . of 
Physicians' 3.059 5.000 5.941 5 . 235 Yes 1 & 3 
Visits 
No. of 
Serum Thea. 1.058a 0.882 1. 176 1. 7611 no HA 
Levels 
No. of 
Inap. Serum None 0 . 471 0.882 1.412 Yes 1 & 3 
Levels 1 & 4 
No . of 
E.R. None None Ilene 0 . 706 Yes 1 & 14 
No. of 
Hasp . None 0.529 0 . 588 2 . 9LI 1 iio NA 
Days 
aAnalysis of variance followed by Post-I!oc test in variables 1, 2 ,3, and 5, Student (t) test in 
variable 4. 
0 \ 
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Table 24. Distance and Travel Time Per Patient in the Experimental 
Group. 
Patient 
Number 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
Patient 
G. p • 
E.S. 
n.s. 
J.K. 
R. G. 
G.F. 
J.H. 
L. G. 
P. P. 
C. A. 
C.D . 
J . B. 
Total 
Mean 
S. D. 
C.H . 
K. C. 
L.S. 
R.J . 
J . J . 
Distance a 
(miles) 
2.2 
2.5 
7 
3 
3.5 
3.2 
3. 1 
2 . 4 
6 
3.1 
3 . 5 
4. 1 
25 
4.2 
4. 1 
7. 5 
12 
96 . 4 
5.67 
5.56 
aDistance is rounded to closest tenth of a mile. 
bTravel time is rounded to the closest minute . 
Travel Timeb 
(minutes) 
7 
7 
15 
6 
10 
10 
10 
5 
12 
10 
7 
7 
30 
5 
7 
10 
10 
168 
9.88 
5.81 
64 
65 
Table 25. Time Bxpended Per Patient by the Clinical Pharmacist \vith 
Six Home Visits. 
Time Expendeda tlo. of Times Total Time/Patient 
Act ivity (minutes) Performed (minu tes ) 
Chart Revie\v 15 15 
Initial Home Visit 40 liO 
Hriting Treatment 
Plan 10 10 
Follow-up Visit 20 5 100 
\'!riting Reports 10 5 50 
Consultation with 
Physician 0 0 7 
Tr ave l Time 20 6 120 
Total 5. 7 hrs. 
avalues listed are the mean times of 17 patients rounded to the nearest 
minute . 
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Table 26. Net Benefit of the Home-Based Pharmacokinetic Service After 
Six Visits. 
Benefits Costs Net 
Resources a ($) ($) 
Pharmacist's Time (5.7 hrs.) 120b 
Hiles Traveled by Pharmacist 
( 6 8 miles) 14c 
Decreased Uo. of Inappropriate 
Serum Levels (1.15)d 34 
Decreased No. of Physicians' 
Visits (2.88)e 99 
Decreased No . of Emergency 
Room Visits (0.71)f 85 
Subtotal 218 134 
Benefits minus Costs 
aFinancial data rounded to the nearest dollar . All data are per 
patient for six months. 
Benefit 
($) 
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bBased upon an hourly salary of $17.43 plus 20% for fringe benefits. 
CEased upon Internal Revenue Service allowable mil eage deduction of 
$0 .205/mile. 
dprojected decrease is based upon the average of the means of the 
groups that were significantly different from the experimental group. 
Benefit is based upon a routine areawide charge of $30 for a serum 
theophylline level. 
eprojected decrease is based upon the mean value of the control group 
that was significantly different from the experimental group . Benefit 
is based upon a routine areawide charge of $34 . 40 for a physician 
office visit. 
fprojected decrease is based upon the mean value of the control group 
that was significantly different from the experimental group . Benefit 
is based upon an areawide minimum charge of $120 for a hospital 
emergency room visit for pulmonary patients. 
DISCUSSION 
This work was designed to initiate specific clinical activities in 
ambulatory settings, and to deterwine or evaluate the usefulness and 
benefits of such activities. The therapy of patients with chronic 
pulmonary diseases who were receiving theophylline for their ailments 
Has monitored at their homes as a type of home-health-care service. An 
evaluation of the overall usefulness of such monitoring, as compared to 
controls, was made. 
In this era of complex and sophisticated therapeutic agents, the 
safe and efficacious use of drugs has become an important issue. This 
requires the delivery of the therapeutic agent to target tissues or 
sites of action within a narrow therapeutic window that allovrs for 
efficacy without toxic reactions. To assure a precise achievement of 
such optimal goals, an overall and continuous monitoring of therapy 
becomes important. 
Nonitoring in the ambulatory setting is important because patients 
are usually on their own in complying with therapy, achieving 
therapeutic efficacy or monitoring for signs and symptoms of toxic 
effects. Community pharmacists, being accessible members of the health 
care team for ambulatory patients, have a vital role to play in the 
overall monitoring of drug therapy. Some of these activities were 
practiced on a community level in this study with encouraging results. 
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In this work , mor.itorinc:; of therapy of outpatients Hith asthma 
and/or COPD 1.,ras attempted to study the ircpact of the clinical pharmacist 
on the health status of this group of chronic patients, and whether the 
effect is cost beneficial. In 1985 the number of reported ambulatory 
(non-institutionalized) COPD cases in the United States was over 
20 millions with 11,618,000 cases of chronic bronchitis and 8 ,61 2 ,000 
cases of asthma (116). This number indicates the importance of the ~I 
investigation of any health maintenance program that aims towards 
improvement of health status of COPD patients. The projected national 
savings could be significant if such a program is cost beneficial as 
Hell. 
In the present work, monitoring of therapy was carried out by means 
of clinical assessment methods as well as measurement of respiratory 
volumes and serum theophylline determinations. 
Clinical assessment, measurement of vital signs, and determinations 
of lung volumes were useful in monitoring therapy. During the monthly 
visits to the experimental group, the health status of each patient was 
assessed by measuring vital signs such as pulse, blood pressure, 
respirations, etc. Furthermore, the chest was also auscultated for 
abnormal sounds. Lung volumes were determined Hith the use of a simple 
hand-held spirometer. At the same time enquiries were made of the 
patients about unusual symptoms or any change in health status that they 
might ascribe to the medication, in addition to enquiries related to 
compliance with drug therapy. 
The use of the hand-held spirometer was a very valuable and simple 
method of determining lung volumes. Its portability and ease of use 
made it very attractive to patients who, by and large, had little 
.... 
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difficulty in learcin: how to operate it properl~ (except for one 
elderly patient Hho sh01red s i gns of diffi cul tics in breathinG after the 
use of the spirometer) . By using the device , the FVC and FEV1 were 
detertlined simply and quickly . These tHo para"neters have been found to 
be a good measur e of pulmonary f unction ( 11 7) and to be valuable in t~e 
estination of ventil ation and its correlation \lith t he serum leve l of 
therapeuti c agents ( 117, 11 8) . 
Exareinin; the results reported in Table 14 indicates a significant 
aver aGe increase i n the ~FEV1/FVC as a resul t of chanGe in therapy . As 
shown i n Table 15 , in the repor t ed serum theophyll i ne concentration values 
before and after the pharmaci st ' s intervention , there was no initial serum 
concent r ation for 2 patients . While the dose of theophyl l ine was 
theoretically adequate in patient (#3 ) , lack of compliance was frankl y 
admitted by the patient . In the case of the other patient (#7) the 
probl em was l ack of compliance as we ll as obvi ous inadequate dosing . It 
was the pharmaci st- physician j udgement that orderi ng any labora tory work 
prior to any chanGe was a waste of resources . A follow- up laborator y 
order would be initiated by the pharnacist at a l ater t i me . 
Examining the reported data in Table 15 indicates a parallel increase 
in measured l ung vol umes with increased ser um theophylline levels . 
Although the changes in both measureroents \-lere positivel y correl ated , as 
shown in Table 16 , these data were not statistically significant at 
p < 0 . 05 . 
The complete battery of pulmonary function tests is mainly used for 
diagnost i c purposes and is not utilized for r out ine monitor ing of drug 
therapy . Additionally, the high cost of perforr.:ing such tests and t he 
inconvenience in terns of time and special laboratory settings roake the 
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routine ~onitoring of dru~ therapy by such tests highly undesirable. 
The small size, portability and ease of use of the hand-held spirometer 
make it particularly adaptable for monitoring lung volunes at home and 
can serve as a good indicator of the adequacy of therapy. 
In addition to monitoring the patient's status by physical 
assessment, the clinical phar~acist also provided pharmucokinetic 
consultation to the attending physician. Serum theophylline level 
determinations were initiated by the clinical pharmacist with prior 
approval of the patient's physician. Patients were counseled on the 
importance of seru~ level measurements in achievinG optimal therapy. It 
is Hell lm01vn that in order to maximize the utilization of laboratory 
data in calculating a proper dosage regimen, one must ascertain that the 
timing of the test is appropriate. To accomplish this, patients were 
made av1are of issues such as steady-state serum concentration of drugs, 
the timing of blood sample withdrawals and the importance of strict 
compliance with the therapeutic regimen during the 24 hours prior to the 
test. Laboratory personnel were also alerted to the importance of 
proper labeling with respect to time of collection. The laboratory 
results were utilized in designing a theophylline dosage regimen that 
would assure proper maintenance therapy. If this was different from the 
previous therapeutic regimen, the clinical pharmacist subsequently 
prepared a report outlining the laboratory data and the results of the 
various physical assessment tests, together with recommendations for a 
change of therapy. The report was submitted to, and discussed with, the 
attending physician who, as a general rule, approved it and included a 
copy of it in the patient's medical charts. 
Table 17 shows that over 93% of the pharmacist's recommendations 
were approved . It is i~portant to note here that the physician's 
approval of the pharmacist's recommendations was not automatic . 
Considerable preparative work and discussions with the physicians had 
been engaged in by the phar~acist prior to the start of the service . 
Still some resistance lingered in the mind of a few; however, as time 
\-rent by, and t he clinical utility of the pharmacist's recoJJlliiendations 
became ap par ent, the attendinc; physicians responded by placing more 
confidence in the recommendations, and holding more respect for the 
clinical pharmacist. 
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Compliance with drug therapy is one of the earliest positive 
endpoints that can be detected and that results from monitoring . It may 
be said that the mere institution of monitoring would have a positive 
psychological effect on patients and lead to improved compliance. This 
may be true , and in addition to that, the reinforcement of prescription 
directions, patient education and counseling have definite pos itive 
effects on compliance Hi th drug therapy ( 119). The results shovr 
definite improvements in compliance. Patients were pleased to be able 
to communicate with a clinical pharmacist and have the outlines of their 
therapy clarified to them. Further , they appreciated being abl e to have 
their enquiries regarding their health status attended to, and to have 
their psychological fears about therapy allayed. It is in t eresting to 
note that this type of rapport was most appreciated by the two extremes 
of age. The elderly felt good about having a health professional look 
after them. The children, appreciating the attention , enjoyed the 
novelty of the home service and participated enthusiastically in 
determining their own FVC and FEV1. 
Laboratory measurements of serum theophylline levels are i mportant 
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in establishinG a baseline of thcra~y f or the i ndividual patient . T~e 
frequency of r epeated measurements can be reduced s i Gnificantly by relyin~ 
on pul monary function tes ts, as carried out in this instance with the aid 
of t he simple ha nd- held spirometer . Good correlations have been docu-
men ted between the Forced Vital Capacity (FVC) and t he Forced Expir a tory 
Volume a t one second (FEV1) and bronchodilator therapy ( 117). Indeed , one 
may use the ~FEV 1 /FVC as a measure of the effectiveness of therapy as one 
usually does with serum t heophylline leve l measur es . Althouc h the r esults 
of this s tudy are encourac ing as shown in Tables 14- 16 , further research 
i s needed to determine the s tatistical si~nificance of these data. 
Cos t Effectiveness 
To determine the i mpact of such ~iliulatory cl i nical pharmacokinetic 
services on health care costs and to evaluate the f eas i bility, desirability 
and fu t ure potential i ties of such services as provided by a clini cal 
pharmacist as a home- health care activity , it Has deemed prudent to carry 
out a Cost/Benefit Analysis (CBA ) study of this service. This was done 
simply by calculat i ng the incurred cost and comparinG i t Hith pr ojected 
savings arising from , or directly resultin8 as a consequence of the 
service . 
Five variabl es affecting the health care costs of chronically i l l 
pulmonary patients were chosen for the purpose of thi s study . These 
Here : ( 1) number of serum theophylline level determinations; (2) number 
of inappropriate serum theophylline level determinations ; (3) number of 
pulmonary- r el at ed visits to physicians' offices; (4) number of days of 
hospitalization secondary to pulmonary probl ems; and ( 5) number of 
emer gency room visits secondary to pulmonary problems . Tables 18 
through 22 give the data collected on these variables for the 
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experimental and the various control groups . Statistic~l tools were 
used to determine the validity of the co~parative data. Statistical 
significance Has used as a yardstick to deter~ine whether a particular 
favorable or cost- saving change could be considered in the study or 
discarded. Table 23 gives an overview of these variables toGether with 
their statistical significance. 
Tables 19 and 20 give the data on seruQ theophylline monitoring . 
Differences in serum theophylline level determinations ordered for the 
experimental and the various control groups were not statistically 
significant. On the other hand there were significant differences (p < 
0. 05) in the number of inappropriate serum theophylline level 
determinations between the experimental group and those of the 
concurrent office control and the concurrent clinic control. The mean 
of these two significant differences amounted to 1.15 laboratory tests 
per patient. This mean value was converted to monetary terms by 
multiplying it by $30 (120), the average cost of a serum theophylline 
level determination in our geographical area . This resulted in a net 
saving of $3 4 per patient, arising from the elimination of inappropriate 
or unnecessary serum theophylline level determinations . 
Identification of samples as inappropriate has been reported i n the 
literature in many fashions which leads to variations of cost/benefit 
calculations. Winter et al ., in a recent publication, considered 
samples being appropriate if they were 11 • • • documented, dravm, 
interpreted and acted upon a correct fashion •• ·" (121). 
Table 18 shows the data related to physicians ' office visits. 
There was a significant difference (p < 0. 05) in the number of pulmonary 
related visits to physicians' offices between the experimental group and 
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the concurrent office controls a~ountinG to 2.89 visits per patient. 
This difference, translated into monetary values at the rate of $34 .40 
per family practice office visit (122), amounted to a net saving of $99 
per patient. 
Hospitalization and emergency roo~ visits secondary to pulmonary 
problens were and usually are the two costliest parameters considered in 
our comparison. Additionally, they are also the most t raumatic 
therapeutic events psychosociolobically , They further indicate a real 
need for serious and intensive monitoring of therapy , 
Tables 21 and 22 give the data related to these parameters . Hhile 
the differences in length of hospital stay between the experimental 
group and control groups were not statistically significant, the fact 
that the experinental group had zero hospital days throughout the 
duration of the service indicates the positive effect and the value of 
the service even though it was not possible to document or quantitate 
that positive effect statistically in this instance , Table 25 shoHs a 
favorable mean significant difference (p < 0.05) of 0.71 emergency room 
visits between the experimental and the concurrent clinic control 
groups , By converting this into monetary values at the rate of $120 per 
emergency room visit, a net saving of $84 per patient is projected (123). 
Table 23 presents an overview of the means of the five variables 
under consideration together with their statistical analysis , It 
provides a quick reference for the values used in the CBA cal culations , 
Cost calculations were simple and straightforward, Costs consisted 
of two main components, travel costs and the monetary equivalence of the 
time expended by the pharmacist calculated on a per patient basis . 
Table 24 shows the actual miles traveled per patient per visit, 
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The r.1ean r:~.ilear;e traveled and the mean tioe spent traveling were 
considered for the purpose of cost calculations. Total miles traveled 
per patient was calculated by multiplying the mean mileage by two and 
multiplying the result by six for the mean total mileage traveled during 
the six-month duration of the service. This gave a mean total mileage 
of 68 miles per patient, which when converted to monetary values (at the 
Internal Revenue Service's alloHable deduction of $0.205/mile) resulted 
in a travel cost of $14 per patient (115). The time component of travel 
was incorporated into Table 26 and considered as part of the total time 
spent by the pharmacist. 
Table 25 reports the amount of time associated with those 
activities directly related to the service. The time elements quoted 
represent the mean value for each activity, and notvrithstanding 
individual variations, represent the minimum time that a skilled and 
trained clinical pharmacist \vould have to spend on each activity. 
Aside from the non-professional travel time, the initial assessment 
of the patient's health status and the monthly r.1onitoring fol low-up 
visits represent the major professional time elements. However, the 
table does not account for the initial investment of time, i.e., the 
considerable professional time spent in preparatory discussions vrith the 
physicians and other professionals involved at the start of the 
service. It is felt that such preparation times must not be included in 
a Cost/Benefit Analysis, not only because it is so elusively 
circumstantial but also because it is a one-time only investment for any 
clinical pharmacist who wishes to provide this kind of service in an 
area. Indeed, once the physicians in an area are made aware of the 
availability of such a service and its value demonstrated to them by any 
clinical pharmacist in a particular ~eo~raphical area , then other 
clinical pharmacists may provide the service without any such initial 
investment of time . 
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Table 26 lists all benefits data of the home- based clinical 
pharmacokinetic service for the duration of the study . As can be seen , 
a positive monetary effect can be achieved with such a service th&t by 
itself is worth pursuing in this era of cost conscious health services. 
Cost/Benefit Analysis was r eported in the literature by a number of 
authors . Chrischil les et al. presented a hypothetical analysis for 
including a clinical pharmacy service in Frunily Practice . The benefits 
assumed were : freed physician time , improved qual ity of care, decreased 
referral rate and i ncreased kept- appointments rate . The costs incurred 
by the family practice clinic included: physici an time spent, increased 
operating expenses and development expenses. Equations that quantify 
each cost or benefit were derived and theoretical savings were assumed 
which were $7500- $2500 annually in a sol o- physician practice with a 
total patient population of 4000 ( 119). 
A different approach was reported by Robinson et al . in an attempt 
to establish a pharmacokinetic consulting service for clinic patients . 
Drug analysis was a major component to facilitate j ustification of third 
party reimbursement . The service included patient interview, review of 
patient chart, drug analysis and writen consul t ation with each serum 
drug concentration. The authors indicated that i nitial cost 
justification was difficult because of the high initial capital outlay , 
due to the inclusion of the drug anal ysis service , not only in space and 
equipment, but personnel , licenses and quality control . The authors 
indicated that the number of drug analyses had to double in order to 
meet the costs , since serum drug analysis charges were the majo~ 
component of revenue (76). 
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Althou~h the need for clinical pharmacist consultation servi c es has 
been demonstrated by many , the method of r e imbursement i s s till 
unclearly defined. To be able to survive independently and be marketed, 
such innovative practice needs cost justification where revenues are 
derived primarily as fees for the service not through other medical 
services . 
In the setting Robinson described, the problem of inadequat e 
follow-up was encountered "• •• which is more likely to occur in an 
ambulatory clinic than a hospital setting ••• " This very important 
issue could probably be resolved by inclusion of home visits as 
described in this work where follow-up was very adequate. 
The above CBA analysis does not take into consideration the 
intangible benefits of the service. As i s the case with s i milar medical 
or health-related services, it is often very difficult to convert these 
intangible benefits into monetary equivalences or to assign them a 
dollar va lue. None theless , this service provided consid erable 
intangible benefits. The i mprovement in general health status, the 
rewarding psychosociological effects and the fuller and richer lives 
that the patients achieve with proper therapy for their ail ments are 
factors that must somehow be considered in any such CBA analysis even 
though they are not assigned numerical values. These are real values 
that cannot be analyzed s t atistically or incorporated into a CBA 
equation. This service resulted in many heartening stories of 
i mprovement in health and enjoyment of life which might sound anecdotal 
but are nonetheless real. 
COJJCLUSI 0!·1 
This study \las undertal~en to investiGate the provizion of 
clinical phar macokinetic services to ambulatory patients with chronic 
obstructive puluonary di sease (COPJ) and/or asth~a . The study was 
perforr;!ed unde r protocol as a type of howe health care service usin6 
patients assiGned t o either the experimental group or one of three 
control [;roups . 
There Has a siGnificant decrease in the number of physician's 
visits for patients in the experimental group. The nucber of seruQ 
l evels ordered inappropriately and the number of emergency room visits 
were significantly lower in the experimental group when compared with 
those of the contr ol groups. There was no sicnificant difference in 
results of t he other variables studied , namely number of serum levels 
and number of days of hospitalization. 
Analysis of the cost and benefit of the service offered to the 
experimental group indicated that the cost was lower than the benefit 
c alculated which concludes that t he service i s cost-beneficial in t he 
population tested. 
It is concluded that t he community based pharmacokinetic service 
had a positive impact on the health status of the patient population 
served . It is also concluded that the participating physicians and 
the popul ation served were hiGhly acceptable of the service . 
The concept of pharmacokinetic monitoring as a hoce health care 
service should be tested in other patient populations to validate the 
findings of t his study. 
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Public Health Service, Food and Druc 
AdministNt tion 1 f.ocl(Ville, 1 ;aryl and 20857) 
l ,V, Dosa3e Guiclines f or Theo~hylline Products 
!lew Intravenous dosac e guide lines were added to the l abelinG of 
theophylline products in April 1978 . FDA ret~inds physicia ns that the 
I. V. infusion rate corn.rnonly used previously 1 is dangerous in some 
patients and t.my result in life-threatening cardiac arrhyth.rnias and 
seizures,2-4 
Although theophylline has been used nany years , priQarily for the 
treatment of asthma, only recently have studies identified t he optioal 
dosage 5uidelines for most patients . Doses must be tailored to the 
medical circumstances in each case, and in selected patients be 
monitored by measurement of serum theophylline concentration. 
Hhen excessive dosases are given , theophylline toxicity including 
seizures and death can result. FDA is aware of reports of such toxicity 
resul ting from commonly used dosage reconwendations1,5 which are 
inappropriate in soue patients. 
Potentially Fatal Seizures 
Potentially fatal theophylline-induced seizures are generally focal 
or grand mal and may occur in persons with no history of convul sive 
disorders . The mor tality rate is more than 50 percent in some 
studi es,6- 9 Seizures may be refractory to anticonvulsant therapy (I . V. 
diazepam, 0 .1 - 0.3 mg/Y.g up to 10 mg) , but usually cease when the drug 
is Hithdrawn and the pl asma concentration falls beloH the critical level 
for the particular patient. In addition, rapid intravenous 
administration of theophylline and its derivatives has caused severe and 
even fatal acute circulatory failure. 
Dosage Guidelines 
The new dosage guidelines for safe intravenous administration of 
theophylline follow, All dosages should be calculated from lean (ideal 
body weight , Theophylline does not distribute into fatty t i ssue . 
Since, in some patients , the difference between therapeutic and 
toxic serum concentrations is small, the safest approach is to 
individualize dosage in conjunction with monitoring of serum 
theophylline levels. 
For oral dosage , various theophylline products are available. The 
equivalent content of anhydrous t heophylline is t he active inGredient 
that determines blood concentration and clinical response. 
If a change in theophylline product is made , thus chan5ing the 
anhydrous theophylline equivalent, the physician should review the 
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Aminophylline Dosas e fo r Patient Population 
I. No currently receivin; theophylline products: 
GPoup 
Children 6 
months to 9 yrs 
Children ace 9-
16 and younG 
Otherwise healthy 
nonsmol~int; adults 
Older patients and 
patients Hith 
cor pulmonale 
Patients with con-
gestive heart 
failure, liver 
disease 
LoadinG Dose + 
6 L1G/ kt:; ;; ( 5 ) 
6 tag/kg "( 5) 
6 mg/ kg !:· ( 5 ) 
llaintenance Dose + 
For !Jext 12 Hours 
1 • 2 m.:;/lq;/hr 
.;; ( 1 • 0 ) 
1.0 ng/kt;/ hr 
''(0.85) 
0 . 7 rcg/ kg/ hr 
"(0 . 6 ) 
0. 6 mg/kG/hr 
"(0.5) 
0 • 5 mg/lq;/ hr 
*(0.4) 
lle.in t enancc 
Dose + Beyond 
12 Hours 
1. 0 m6/lq;/hr 
ii ( 0 . 85 ) 
0. 8 mg/k~/hr 
·:: ( 0 . 7) 
0.5 !Tl[;/k~/ilr 
i) ( 0.4 3) 
0.3 El[.;/kt;/hr 
~'(0 .26) 
0.1-.2 r.Jg/kG/hr 
ii ( 0. 1 ) 
w Equivalent anhydrous theophylline dose indicated in parentheses 
+ Based on estimated l ean (ideal) body weicht 
II. Currently receiving theophylline products: 
Determine , where possible, the 
amount, route of administration, 
and form of the patient's last 
dose. The dosage should be 
based on theophylline equivalence 
( 1 • 2 rag of aminophylline is 
equivalent to 1.0 mg of theo-
phylline). 
The loading dose for theo-
phylline should be based on the 
general expectation that each 0.5 
mg/kg (of lean or i deal body 
weight) of theophylline admin-
istered as a loading dose will 
result in a 1 mcg/ml increase in 
serum theophylline concentration. 
Ideally , then , the loadi ns dose 
should be deferred until a serum 
theophylline concentration can be 
rapidly obtained. If this is not 
possible, the clinician must 
exercise judgment in selecting a dose 
that has a potential for benefit with 
minimum additional risk . \'!hen there 
is sufficient respiratory distress 
to \·!arrant a scall risk , 2. 5 mg/kr; 
of intravenous theophylline (2.9 ns/ 
kg aminophylline) is likely to 
increase further the serum concentra-
tion by only about 5 mcg/ml . If the 
patient is not already experiencing 
theophylline toxicity, the risk of 
dangerous adverse effects from this 
dose is low 
Aft er this modified loading dose, 
the maintenance dosage recommenda-
tions, in this group of patients, 
ar e the sa~e as t hose described 
above. 
theophylline equivalent of t he new medication i n order to avoid 
overdosar,e or underdosage . 
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The effic acy of any theophylline product is dependent upon t he 
attai nraent of a serum concentration of approxinate l y 10- 20 mcc;/r.:l . The 
risk of toxicity increases as seru::J concentrations exceed 20 ncc/r:ll. 
; .. :any factors affect the serun: theophylline level s . Theophylline is 
90 percent metabolized by the liver to several inactive metabolites . 
The clearance of theophylline is lar~ely dependent on l i ver ruction and 
ne tabolic factors. In adults with normal l iver and cardiac function and 
stable lung disease , t heophylline half- life averages 4- 5 hours and may 
range from 3 t o 9 . 5 hours. 
It i s desirable to l:lOnitor serum levels of asthoatics who are on 
chronic theophylline therapy . When measuring serum theophylline 
concentrations for the purpose of proper dose adjustment , ffiea sur ement of 
trouGh levels as well as peak level s should be rnade. 
Ti1eophylline Pharrnacol~inetics Project at Li ncoln lledica l Group 
A. Pharr;;acokinetics Dosing and !·:oni t or inc 
1. Determine the Loading Do~e (L. D.) 
a . 6 ms/kg based upon l ean body Hei ght 
b . Decrease the L. D. by 50-1 00% if the patient ha3 
received a t her apeut i c dose in the last 24 hours. 
c . Evalua t e L. D. by evaluatin;; trout; ll seru:n l evels . 
d . L. D. may be Given orally or parenterally . Oral 
preparation may be compressed tablets or sustained 
r elease dosage forra. 
9 1 
2. One serum l e vel will be drawn prior to initiation of therapy , 
if the patient has had a therapeutid dose durinG the past 
24 hours . 
3. A second level ( trou~h) Hill be dravm 24 hours after 
initiatinG therapy. This Hill be utilized to es timate 
Kel, t-1/2, and time needed for s teady state. Volume of 
distribution Hill be calculated froc the literature. 
4. Another level will be obtained at the ac tual steady stat e , 
(i.e., three days after initiation of therapy Hith no missed 
doses ). 
5. Follow-up of the Patient . 
A fol l oH-up plan Hill be performed by the clinical pharmacist, 
to include 
a. Contacting the patient monthly to counsel the patient 
on medication use and to assess patient r esponse 
to ther apy. 
b. llaking home visits to the patient to perform 
assessments . 
B. Cost- Benefit Ana lysis 
One of the ~oals of this study i s to perform a cost-benefit 
ana lysis of the role of a clinical pharmacist in a pharrnacokinetic 
dos ins service for ambulatory patients. An evaluation of the home 
vis its Hill also be made along with measures of the cost of the 
various components of the pharmacol~inetics dos ing and monitoring of 
theophylline therapy . 
.. ·.· 
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Patient Information For~ 
You are requested to participate in a project conducted by flay 1!, 
ilikhail, a phar~acist and a gr aduat e s tudent in the School of Pharmacy , 
University of the Pacifi c , 
The purpose of this project is to evaluate the effectiveness of a 
phartJacist in UJoni to ring your r esponse to Theophylline , Hhich is an 
excellent medi cation for your breathin.r; . I;easuring blood l evel s of 
theophylline i s a cownon way to prescri be theophylline , The pharmacist 
Hill us e measurements of theophylline blood levels to help deter~ine how 
much t heophylline you should r eceive. The pharmacist Hill follow your 
progr ess and give advice regarding your medication . For a period of 
6- 12 months the pharmacist wil l meet Hith you a t your home , or elsewhere 
if so indicated, to evaluate your status and response to the 
theophylline, 
This project has been approved by the Lincoln Medical Group, 
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Patient Consent For~ 
I ----------------------
agree to participate in t he Theophylline 
project conducted by l~ay N. l·likhail , a pharmacist and ;;raduate student 
of the School of Pharmacy, University of the Pacific. 
I understand the following : 
1. Theophylline blood levels Hill be measured at appropriate 
times, and the results will be used as a cuide for prescribing 
theophyl line for me . 
2 . After my theophylline prescription is determined, there will 
be a follO\:- up of ray status by the pharmacist over a period of 
6- 12 r.10nths . 
3. All information will remain confidential. 
4. I have the right to ask questions prior to and durinG the 
study . 
5 . I have the right to asl~ ~lay t-~ikhail and my physic i an for 
advice reGarding my medication . 
6. The procedure for this project has been approved by Lincoln 
Hedical Group . 
Signature: 
Date : 
